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Summary 
Introduction 
This systematic review evaluates the following research questions:  
 Is defibrotide for the prophylaxis of veno-occlusive disease (VOD) for 
patients undergoing haematopoietic stem cell transplantation (HSCT) 
in comparison to no prophylaxis, placebo or other experimental op-
tions in adult and paediatric patients more effective and safe concern-
ing overall and disease-specific mortality, incidence of VOD, quality 
of life and adverse events? 
 Is defibrotide for the treatment of severe veno-occlusive disease (VOD) 
after oncologic therapy or after haematopoietic stem cell transplanta-
tion (HSCT) in comparison to no treatment, placebo or other experi-
mental options in adult and paediatric patients more effective and safe 
concerning overall and disease-specific mortality, resolution of VOD, 
quality of life and adverse events?  
VOD is a rare disease most often occurring as a result of a conditioning treat-
ment administered prior to HSCT; hepatic sinusoidal endothelial cell lesions 
are deemed to be the primary cause. Characteristic symptoms are painful he-
patomegaly, right upper quadrant pain, jaundice and ascites; VOD is diag-
nosed by either the Seattle criteria or the Baltimore criteria. For patients un-
dergoing HSCT, varying estimates for the frequency of VOD are given. The 
mean incidence reported from a study evaluating the incidence of VOD in 
patients undergoing HSCT across 135 studies ranged between 0 and 62.3%, 
with a mean incidence of 13.7%. However, in the majority of studies (130/ 
135), the variation in incidence ranged from 0 to 40%. The natural course of 
the disease depends on its severity, which is based on clinical features that 
can be assigned only retrospectively. Severe VOD is associated with a high 
mortality rate of 84.3% and progression to multi-organ failure (MOF) in most 
of these patients.  
Defibrotide is a large, single-stranded deoxyribonucleotide with antithrom-
botic, profibrinolytic and anti-inflammatory effects; the precise mechanism 
of action is unclear. For the treatment of VOD, defibrotide is indicated in 
patients with severe VOD at a dosage of 25 mg/kg per day (same dosage for 
children and adults), divided into four doses for a minimum of 21 days, and 
should be continued until the symptoms and signs resolve. For the prophy-
laxis of VOD in adults and children undergoing allogeneic stem cell trans-
plantation with risk factors (pre-existing hepatic disease, second myeloabla-
tive transplant, allogeneic transplant for leukemia beyond second relapse, con-
ditioning with busulfan-containing regimens, prior treatment with gemtuzu-
mab ozogamicin, diagnosis of primary haemophagocytic lymphohistiocyto-
sis, adrenoleukodystrophy or osteopetrosis), the recommended dosage of de-
fibrotide is 6.25 mg/kg i.v. four times daily. 
In September 2013, the European Medicines Agency (EMA) granted market-
ing authorisation for Defitelio® “for the treatment of severe VOD also known 
as sinusoidal obstructive syndrome (SOS) in HSCT therapy”. The market au-
thorisation was granted “under exceptional circumstances”, and Defitelio® is 
under additional monitoring. Defibrotide is not approved for the prophylaxis 
of VOD. 
VOD is a rare disease, 
often associated with 
conditioning regimens 
prior to HSCT 
defibrotide: 
antithrombotic, 
profibrinolytic and  
anti-inflammatory 
disease 
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For the prophylaxis of VOD after HSCT therapy, no standard therapy exists. 
UDCA and low-dose heparin are in clinical use, but they are not approved 
for this indication. The British Committee for Standards in Haematology and 
the British Society for Blood and Marrow Transplantation recommend de-
fibrotide at a dose of 6.25 mg/kg i.v. four times daily for children (level of 
recommendation is 1A = strong recommendation with high quality of evi-
dence) and for adults (level of recommendation is 2B = weak recommenda-
tion based on moderate quality of evidence) undergoing allogeneic SCT who 
additionally have any of the following risk factors: pre-existing hepatic dis-
ease, second myeloablative transplant, allogeneic transplant for leukaemia be-
yond second relapse, conditioning with busulfan-containing regimens, prior 
treatment with gemtuzumab ozogamicin, diagnosis of primary hematophago-
cytic lymphohistiocytosis, adrenoleucodystrophy or osteopetrosis. Also for the 
treatment of VOD, the committee recommends defibrotide for both adults and 
children (level of recommendation is 1B = strong recommendation based on 
moderate quality of evidence). 
For the treatment of VOD no standard therapy is available; the mainstay of 
VOD therapy is supportive care. Tissue plasminogen activator (t-PA), N-ace-




To evaluate the effectiveness and safety of defibrotide for the treatment and 
prophylaxis of VOD, a systematic literature search in four databases was con-
ducted in December 2014 and a Scopus search in January 2015. Furthermore, 
the market authorisation holder was contacted to submit relevant publications.  
Two review authors independently selected the literature. In addition, one 
review author extracted data from the included studies and a second review 
author checked the extracted data regarding completeness and accuracy. In 
cases of disagreement, consensus was achieved through discussion or by in-
volving a third person. The risk of bias and the strength of evidence (accord-
ing to GRADE) were assessed. 
 
Results 
Prophylaxis of VOD 
For evaluating the effectiveness and safety of defibrotide for VOD prophy-
laxis, three studies with a total of 563 patients were included overall: one 
randomised controlled trial (RCT) conducted in a paediatric study popula-
tion and two historical controlled trials (one trial included children only; the 
other trial included both adults and children). The RCT compared defibro-
tide to no prophylaxis of VOD in overall 356 patients. Both groups received 
treatment with defibrotide once VOD had developed and about one third in 
each group received ursodeoxycholic acid (UDCA) as concomittant prophy-
lactic therapy. In the historic controlled trials, patients in the control group 
received either UDCA or tinziparin as prophylaxis or low-dose heparin was 
compared to low-dose heparin in combination with defibrotide.  
All three studies assessed overall mortality at 100 days after transplant. The 
RCT did not find a statistically significant difference between the two groups 
(both 10%), but this outcome may have been biased due to the administra-
tion of therapeutic defibrotide after development of VOD in both groups of 
no standard therapy  
for VOD prevention 
available 
mainstay of  
VOD therapy is 
supportive care 
three prevention  
studies included 
Summary 
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the trial; additionally, one-third of the patients in each group received con-
comitant UDCA. One of the historical controlled trials also calculated the 
statistical significance between their groups and showed no significantly re-
duced mortality rate for defibrotide (p=.07).  
All three prophylaxis studies calculated the incidence of VOD (the incidence 
of VOD by 30 days after HSCT was the primary endpoint of the RCT), rang-
ing from 0–12% in the intervention groups to 7–20% in the control groups. 
In the RCT, the incidence of VOD was 12% in the intervention group and 
20% in the control group closely reaching statistical significance. In one of 
the historical controlled studies the difference was with 0% in the defibro-
tide group in comparison to 19% in the control group also statistically sign-
ficant. According to two studies, disease-specific mortality was 0–2% in the 
defibrotide group and 6% in the control groups which was not statistically 
significant. These results have to be interpreted against the background of 
different criteria used for the diagnosis of VOD.  
Results of the RCT showed that the incidence of acute graft-versus-host-
disease (GVHD) by day +30 was 34% in the defibrotide arm compared to 
52% in the control arm (p=.0057). By day + 100, the incidence was 47% in 
the defibrotide group and 65% in the control group (p=.0046). The incidence 
of chronic GVHD did not differ between the groups by 180 days. In one of 
the historically controlled trials, the incidence of acute GVHD grade ≥II was 
34% in the study group versus 38% in the control group (p=.58). Authors of 
the other historically controlled trial reported the occurrence of GVHD in 
two patients of the defibrotide group, no information was provided for the 
occurrence of GVHD in the control group. 
In terms of safety, both historical controlled studies did not provide exact data 
on the occurrence of overall adverse events (AEs). Results from the RCT showed 
that 87–88% patients had AEs and 37% had severe AEs. However, treatment-
related AEs were reported in only 6% of patients receiving defibrotide and 
in 4% of patients in the control group. Severe treatment-related AEs (Grade 3) 
occurred in 2% of defibrotide arm patients and in 3% of control arm patients. 
However, these numbers have been measured after defibrotide treatment was 
administered in both study arms to all patients who had developed VOD.  
Treatment of VOD 
The results based on the currently available evidence for defibrotide treatment 
of VOD (one dose-finding RCT and one prospective case series with overall 
239 patients) showed similar rates for overall mortality on day +100 (58–
65%). For disease-specific mortality + 100 days, results were only available 
from the dose-finding RCT (28–29%). A complete response of VOD was re-
ported in 36–46% of patients. 
Data on AEs were only provided in the dose-finding study. High rates of AEs 
were reported from both treatment arms; comparing the two different dosages, 
no statistically significance was reported (p=.367). However, treatment-re-
lated AEs occurred in 8% of patients overall, of which 3% were of grade 3–4. 
No grade 5 treatment-related AE occurred and no treatment-related deaths 
were reported. Treatment-related bleeding of grade 3–4 was reported in 1% 
of all treated patients. 
No evidence was found on the effect of defibrotide on patients’ quality of life. 
Regarding the fact that VOD is a potential life-threatening disease and that 
patients suffering from severe VOD are critically ill, the outcome for this end-
point is relevant, but might be secondary. 





two studies included 
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Upcoming evidence 
One parallel, randomised study, evaluating the efficacy and safety of defib-
rotide for the prophylaxis of VOD was identified. 
Two defibrotide treatment studies, both single-arm, are ongoing. 
Reimbursement 
According to the submission documents received from the Ministry of Health 
(MoH), defibrotide is currently not included in the Austrian catalogue of 
benefits. Assuming an average body weight of 70 kg for adults, 1,750 mg de-
fibrotide are needed per day (i.e., 6.25 mg/kg every six hours). Defibrotide is 
available in vials containing 200 mg, costing € 426. For the administration of 
1,750 mg, nine vials would be needed, corresponding to daily treatment costs 
of € 3,834. Assuming a treatment duration for a minimum of 21 days, costs of 
€ 80,514 would occur.  
The costs for defibrotide for VOD prophylaxis are hard to calculate due to 
the unclear duration of administration. In the included RCT patients who 
were allocated to the intervention group received defibrotide for VOD pro-
phylaxis for a median of 35 days (range 4–71 days). Thus, assuming a dura-
tion of 35 days for VOD prophylaxis, costs of € 134,190 would occur. 
According to information submitted by the applicants, defibrotide was used 
in Austria off-label for over ten years in patients who developed VOD after 
high-dose chemotherapies with consecutive autologous or allogeneic HSCT. 
For many years, defibrotide was available as Prociclide® (approved for the 
treatment of deep vein thrombosis) for approximately € 350 per treatment 
cycle. Later, the marketing authorisation was withdrawn in the context of a 
prospective approval study (indication: VOD). The EMA approval (under ex-
ceptional circumstances) of Defitelio® for the treatment of VOD was associ-
ated with a substantial price increase of the drug.  
 
Discussion 
Currently, the evidence for both possible indications of defibrotide is scarce. 
Due to the rarity of disease, RCTs, foremost for defibrotide therapy,are dif-
ficult to conduct. A search in two databases was conducted and two defibro-
tide treatment studies (both single-arm), and one study, evaluating the effi-
cacy and safety of defibrotide for the prophylaxis of VOD (parallel, random-
ised) were identified (see Appendix Section “Ongoing research”. The pauci-
ty of evidence leaves several questions unanswered: 
 Drug administration: Different dosages were used for prophylaxis as 
well as for the treatment of VOD, ranging from 10 mg/kg/day – over 
25 to 60 mg/kg/day. According to the British Committee for Standards 
in Haematology and the British Society for Blood and Marrow Trans-
plantation, defibrotide is recommended at a dose of 6.25 mg/kg four 
times daily for the prevention and treatment of VOD in children and 
adults. However, the guidelines mention that further work is required 
to investigate the optimal dose of defibrotide. Furthermore, the dura-
tion of administration differed. Thus, the optimal duration and the op-
timal dosage remain unknown, even though there are some indications 
that lower doses are associated with fewer adverse events. In addition, 
defibrotide is also available as oral therapy, even though this route of 
administration was not used in any of the studies. How these differ-
 
defibrotide treatment: 
costs of € 80,514 per 
treatment cycle 
Summary 
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ent applications affect outcomes has not been assessed. In addition, no 
information on differences concerning oral versus intravenous admin-
istration was found.  
 Different criteria (Baltimore- or modified Seattle criteria) were used 
for the diagnosis of VOD. Depending on the criteria used, a different 
set of patients at different stages of disease will be identified.  
 A further question concerns whether defibrotide therapy should be pre-
ferred over VOD prophylaxis. Foremost, since younger age has been 
identified as a risk factor for the development of VOD, the prophy-
laxis with defibrotide may yield better outcomes than therapy in this 
age cohort. Concerning prophylaxis, guidelines recommend defibro-
tide for high-risk patients only. The effectiveness of defibrotide pro-
phylaxis remains unknown in children at low risk and in an adult 
population. 
 Besides age, several further risk factors for the development of VOD 
have been characterised. Thus, the reduction of risk factors and risk 
stratification for VOD are keys to minimise VOD occurrence.  
 Currently, no long-term data on safety is available for defibrotide. 
 
Conclusion 
Defibrotide for VOD prophylaxis 
Overall, the strength of evidence for the effectiveness and safety of defibro-
tide for the prophylaxis of VOD was very low to moderate.  
Even though there are indications that the prophylaxis of VOD with defibro-
tide reduces the incidence of VOD, a life-threatening disease, at least in chil-
dren at high risk and few adverse events are associated with this therapy, an 
inclusion in the catalogue of benefits for an off-label indication cannot be 
recommended.  
A re-evaluation is recommended when the licensing status of the drug changes.  
Defibrotide for VOD treatment 
Overall, the strength of evidence for the effectiveness and safety of defibrotide 
for the treatment of VOD is very low. 
The current evidence is not sufficient to evaluate the effectiveness and safety 
of defibrotide for the treatment of VOD. Since VOD is a rare and life-threat-
ening disease with no other therapeutic options available, defibrotide offers 
a new therapeutic approach for patients with severe VOD and meets an area 
of high unmet clinical need. Therefore, an inclusion in the catalogue of ben-
efits is recommended with restrictions. 
The proper assessment of risk factors and, whenever possible, the avoidance 
of factors contributing to the development VOD have to be ensured. Data on 
outcomes, foremost on long-term safety, should be collected in a prospective 
patient registry. Re-evaluation is recommended once these data become avail-
able. Thus, EMA website surveillance is also recommended to identify any 
change in the licensing status. Risk-sharing agreements are also indicated.  
 
VOD prophylaxis: 
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Zusammenfassung 
Einleitung 
Indikation und therapeutisches Ziel 
Ziel dieses systematischen Reviews ist, die Wirksamkeit und Sicherheit von 
Defibrotid (Defitelio®) für zwei verschiedene Indikationen zu evaluieren: 
 Ist Defibrotid für die Prophylaxe der hepatischen veno-okklusiven 
Erkrankung (VOD) für PatientInnen nach Stammzelltransplantation 
(HSCT) verglichen mit keiner Prophylaxe, Placebo oder experimentel-
len Möglichkeiten bei Erwachsenen und Kindern wirksamer und siche-
rer hinsichtlich der Gesamtsterblichkeit, der krankheitsspezifischen 
Sterblichkeit, der Inzidenz der VOD, der Lebensqualität und Neben-
wirkungen? 
 Ist Defibrotid für die Therapie der hepatischen VOD für PatientInnen 
nach onkologischer Therapie oder HSCT verglichen mit keiner Pro-
phylaxe, Placebo oder experimentellen Möglichkeiten bei Erwachse-
nen und Kindern wirksamer und sicherer hinsichtlich der Gesamt-
sterblichkeit, der krankheitsspezifischen Sterblichkeit, der Rückbil-
dung der VOD, der Lebensqualität und Nebenwirkungen? 
Beschreibung der Technologie 
Defibrotid wird durch kontrollierte Depolymerisation von Desoxyribonucle-
insäure (DNA) aus der Darmschleimhaut von Schweinen hergestellt. Defi-
brotid weist antithrombotische, profibrinolytische und antientzündliche Ei-
genschaften auf, der genaue Wirkmechanismus ist jedoch noch ungeklärt. 
Die hepatische VOD zählt zu den seltenen Erkrankungen und kann Erwachse-
ne und Kinder betreffen. Als primäre Ursache der VOD wird eine Schädigung 
von Lebersinusoiden angenommen, welche in weiterer Folge zum Verschluss 
kleiner Lebervenen führt. Am häufigsten wird die Erkrankung durch Kondi-
tionierungstherapien im Vorfeld von HSCT ausgelöst. Seltenere Ursachen 
können vorangegangene Chemotherapien, hochdosierte Strahlentherapien, 
die Aufnahme von toxischen Alkaloiden sowie Lebertransplantationen sein. 
Charakteristische Symptome der Lebervenen-Verschlusskrankheit sind Schmer-
zen im Oberbauch (rechter oberer Quadrant), schmerzhafte Lebervergröße-
rung, Ikterus und Ascites.  
Die in Studien angegebenen Inzidenzen variieren stark. Eine Untersuchung 
der Inzidenzen der VOD in 135 Studien (die PatientInnen hatten sich einer 
HSCT unterzogen) ergab eine mittlere Inzidenz von 13,7 % (0–62,3 %), wo-
bei in 130 der insgesamt 135 Studien die Inzidenz zwischen 0 und 40 % vari-
ierte. Die Erkrankung kann in verschiedenen Schweregraden verlaufen, wo-
bei die schwere VOD mit einer Mortalitätsrate von 84,3 % assoziiert ist und 
zu Multiorganversagen führen kann. 
Risikofaktoren für die VOD sind vorbestehende Lebererkrankungen, die Art 
der Konditionierungstherapie (höheres Risiko bei der Anwendung von Cyc-
lophosphamiden oder hochdosierter Strahlentherapien), die Art des Trans-
plantates (Risiko höher bei allogenen Transplantaten), das Alter der Patien-
tInnen (Kinder <7 Jahren erkranken häufiger), schlechter Zustand der Pa-
tientInnen bei Behandlungsbeginn, vorangegangene abdominale Strahlenthe-
rapie, Erkrankungen wie Osteopetrosis, primäre hämophagozytische Lym-
Ziel: Sicherheit und 
Wirksamkeit von 
Defibrotid Therapie  
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phozytose oder Adrenoleukodystropie sowie Therapien zur Prophylaxe der 
Graft-versus-Host-Reaktion (GvHR). 
Die Diagnosestellung der VOD kann entweder basierend auf den Seattle-
Kriterien oder den Baltimore-Kriterien gestellt werden. Differentialdiagnos-
tisch sollten Erkrankungen, die ebenfalls zu Leberversagen führen können 
(z. B. Budd-Chiari Syndrom, akute GvHR, hepatische Infektionen oder Arz-
neimitteltoxizität) ausgeschlossen werden.  
Ein wichtiger Faktor bei der Behandlung der VOD ist, unabhängig vom 
Schweregrad der Erkrankung, bestmögliche supportive Behandlungsmaßnah-
men zu ergreifen. Dabei wird besonderes Augenmerk auf den Flüssigkeits-
haushalt, das intravaskuläre Volumen und die Nierenperfusion gelegt, um die 
Ansammlung freier Flüssigkeit einzuschränken. Außerdem sollte die Anwen-
dung potentiell leberschädigender Substanzen vermieden werden. 
Defibrotid erhielt 2004 von der EMA eine Orphan Drug Designation für die 
Therapie der hepatischen VOD. Im März 2013 erfolgte eine negative Stel-
lungnahme des Committee for Medicinal Products for Human Use (CHMP) 
zu Defibrotide für die Therapie und die Prophylaxe der VOD aufgrund me-
thodologischer Mängel der bereitgestellten Evidenz sowie Mangel an Daten 
bei PatientInnen mit eingeschränkter Nierenfunktion. Im September 2013 er-
teilte die EMA für Defitelio® für die Therapie schwerer venookklusiver Er-
krankung bei HSCT nach einem erneuten Zulassungsantrag aber die Mark-
zulassung. Die Marktzulassung erfolgte unter „außergewöhnlichen Umstän-
den“, außerdem unterliegt das Arzneimittel einer zusätzlichen Überwachung. 
Defitelio® ist, nachdem der Hersteller seinen Zulassungsantrag für die VOD 
Prophylaxe zurückgezogen hatte, nicht für diese Indikation zugelassen. 
In den USA erhielt Defitelio® von der FDA keine Marktzulassung, ist aber 
im Rahmen eines „expanded access“ Protokolls erhältlich. Defibrotid erhielt 
2003 für die Therapie und 2007 für die Prävention der hepatischen VOD ei-
ne Orphan Drug Designation von der FDA. 
Für die Behandlung der hepatischen VOD gibt es derzeit keine Standardthe-
rapie, die Erkrankung kann mit den bestmöglichen supportiven Behandlungs-
maßnahmen und Defibrotid behandelt werden. Für diese Indikation wird 
Defibrotid in einer Dosierung von 6,25 mg/kg i. v. alle 6 Stunden (25 mg/kg/ 
Tag) für mindestens 21 Tage verabreicht, bis sich die Symptome der schwe-
ren VOD auflösen. Die Dosierung ist für Erwachsene und Kinder gleich. In 
klinischem Gebrauch sind außerdem der gewebespezifische Plasminogenak-
tivator (t-PA), N-Acetycstein sowie Methylprednisolon. 
Für die Prophylaxe der hepatischen VOD gibt es derzeit keine Standardthe-
rapie. Zwei Substanzen (beide nicht für diese Indikation zugelassen) sind in 
klinischem Gebrauch: Ursodesoxycholsäure (UDCA) und niedrig dosiertes 
Heparin. Die Anwendung der beiden Arzneimittel wird durch Ergebnisse aus 
randomisierten Studien unterstützt. Das British Committee for Standards in 
Haematology und die British Society for Blood and Marrow Transplantation 
empfehlen Defibrotid in einer Dosierung von 6,25 mg/kg 4 mal täglich für 
Kinder (Grad der Empfehlung ist 1A = starke Empfehlung mit hoher Qualität 
der Evidenz) und für Erwachsene (Grad der Empfehlung ist 2B = schwache 
Empfehlung basierend auf mäßiger Qualität der Evidenz), die sich einer al-
logenen HSCT unterzogen hatten und Risikofaktoren (z. B. eine vorbestehende 
Lebererkrankung, Konditionierungstherapien mit Busulfan, Osteopetrosis) auf-
weisen. Auch die Therapie der VOD mit Defibrotid, wird von dem Kommittee 
sowohl für Kinder als auch für Erwachsene empfohlen (Grad der Empfehlung 
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Methoden 
Klinische Wirksamkeit und Sicherheit 
Zur Evaluierung der klinischen Wirksamkeit der VOD Prophylaxe mittels 
Defibrotid wurden folgende Outcomes als wesentlich erachtet: die Gesamt-
sterblichkeit, die krankheitsspezifische Sterblichkeit, die Inzidenz von VOD 
sowie die Lebensqualität der PatientInnen. Um die klinische Wirksamkeit 
von Defibrotid für die Therapie der VOD zu evaluieren, wurden die Outcomes 
Gesamtsterblichkeit, krankheitsspezifische Sterblichkeit, das Abklingen der 
Symptome der VOD und die Lebensqualität der PatientInnen als ausschlag-
gebend erachtet. 
Zur Evaluierung der Sicherheit von Defibrotid für die VOD Prophylaxe und 
Therapie wurden das Auftreten von schwerwiegenden Nebenwirkungen und 
mit der Behandlung im Zusammenhang stehenden Nebenwirkungen als we-
sentlich erachtet. 
Relevante Informationen wurden durch eine im Dezember 2014 durchgeführ-
te systematische Literatursuche in 4 Datenbanken (Medline via Ovid, Em-
base, The Cochrane Library and CRD) gewonnen und durch eine Scopus-
Suche (Jänner 2015) ergänzt. Auch der Hersteller wurde kontaktiert.  
Relevante Daten für die Wirksamkeit und Sicherheit von Defibrotide für 
die Therapie und Prophylaxe wurden in Extraktionstabellen (siehe Tabellen 
A1-1 bis A1-3) dargestellt. Die Beurteilung der internen Validität der inklu-
dierten Studien ist in den Tabellen A2-1 bis A2-3 ersichtlich. Die Qualität 
der vorliegenden Evidenz wurde anhand der GRADE-Methode beurteilt.  
 
Ergebnisse 
Prophylaxe von VOD 
Um die Wirksamkeit von Defibrotid für die Prophylaxe von VOD zu evalu-
ieren, wurden 3 Studien inkludiert: eine randomisierte, kontrollierte Studie 
(RCT) und 2 historisch kontrollierte Studien mit insgesamt 563 inkludier-
ten PatientInnen (alle PatientInnen hatten sich einer HSCT unterzogen). An 
zwei der Studien nahmen ausschließlich PatientInnen unter 18 Jahren teil, 
in der dritten Studie hatten die StudienpatientInnen ein mittleres Alter von 
etwa 37 Jahren. Die meisten PatientInnen hatten eine allogene HSCT erhal-
ten, davor war Busulfan in 15–59 % der PatientInnen verabreicht worden. 12–
34 % der PatientInnen wiesen eine vorbestehende Lebererkrankung auf. Pa-
tientInnen konnten am RCT teilnehmen, wenn zumindest ein Risikofaktor 
für VOD vorlag.  
Insgesamt wurden 279 PatientInnen mit Defibrotid behandelt. Die Dosie-
rungen variierten zwischen 10 und 25 mg/kg pro Tag für 20–30 Tage nach der 
Transplantation.  
Die 284 PatientInnen der Kontrollgruppe (176 PatientInnen im RCT, 56 bzw. 
52 PatientInnen in den beiden historisch kontrollierten Studien) erhielten 
kein Defibrotid zur VOD Prophylaxe (n=228), erhielten jedoch dieselbe Be-
gleitmedikation wie die PatientInnen der Interventionsgruppe. Dies waren, 
je nach Studie, entweder niedrig dosiertes Heparin, UDCA, oder UDCA und 
Tinziparin (als VOD Prophylaxe für HochrisikopatientInnen in einer der 
historisch kontrollierten Studien). 
wesentliche  
Outcomes 
systematische Suche in 
4 Datenbanken  
3 Studien für Prophylaxe 
eingeschlossen 
1 RCT, 2 historisch 
kontrollierte Studien 
Zusammenfassung 
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VOD wurde in zwei Studien (RCT und historisch kontrolliert) unter der Ver-
wendung der modifizierten Seattle-Kriterien diagnostiziert, in der dritten Stu-
die (historisch kontrolliert) wurden die Baltimore-Kriterien zur Diagnose 
angewandt. Die Nachbeobachtungsdauer betrug (falls berichtet) 180 Tage 
beziehungsweise 57 Monate. 
Der RCT inkludierte insgesamt 356 PatientInnen unter 18 Jahren mit min-
destens einem Risikofaktor für VOD. Die PatientInnen wurden entweder der 
Interventionsgruppe (n=180) oder der Kontrollgruppe (n=176) zugeteilt. Die 
PatientInnen der Interventionsgruppe erhielten Defibrotid (25 mg/kg/Tag), 
vom ersten Tag der Konditionierungstherapie bis 30 Tage nach der Trans-
plantation oder, im Fall der Entlassung aus dem Krankenhaus vor Erreichen 
der 30 Tage, für mindestens 14 Tage. Die PatientInnen der Kontrollgruppe 
erhielten keine VOD Prophylaxe. 68 % der PatientInnen der Interventions-
gruppe hatten sich einer allogenen HSCT unterzogen, bei 29 % (Interventi-
onsgruppe) und 31 % (Kontrollgruppe) der PatientInnen wurde eine autolo-
ge HSCT durchgeführt. Der primäre Endpunkt, die Inzidenz von VOD war 
mit 12 % in der Interventionsgruppe und 20 % in der Kontrollgruppe gerade 
statistisch signifikant (p=.0488). Hinsichtlich der Gesamtsterblichkeit und 
der VOD-assoziierten Mortalität konnten keine Unterschiede zwischen Pa-
tientInnen mit prophylaktisch angewandtem Defibrotide und PatientInnen 
ohne Prophylaxe festgestellt werden. Allerdings erhielten PatientInnen bei-
der Gruppen bei Auftreten einer VOD Defibrotid als Therapie, wodurch die 
Möglichkeit der Verzerrung der Studienergebnisse besteht. Zusätzlich erhielt 
etwa ein Drittel der PatientInnen in beiden Gruppen UDCA als Begleitme-
dikation. Eine der beiden historisch kontrollierten Studien, in welche auch 
Erwachsene inkludiert wurden, zeigte eine verminderte Inzidenz von VOD, 
während in der zweiten historisch kontrollierten Studie kein statistisch signi-
fikanter Unterschied festgestellt werden konnte. In einer der historisch kon-
trollierten Studien wurde die Mortalitätsrate im Vergleich beider Gruppen 
mit p=.07 als nicht statistisch signifikant berechnet.  
Die Inzidenz der akuten GvHD war im RCT sowohl an Tag 30, als auch an 
Tag 100 nach der HSCT in der Defibrotidgruppe statistisch signifikant nie-
driger. Keinen Unterschied gab es hinsichtlich der Inzidenz der chronischen 
GvHD an Tag 180 nach der HSCT. In einer der historische kontrollierten 
Studien wurde die Inzidenz der akuten GvHD (Grad ≥ 2) mit 34 % in der 
Defibrotidgruppe und 38 % in der Kontrollgruppe angegeben (p=.58). In der 
zweiten historisch kontrollierten Studie trat die GvHD bei zwei PatientInnen 
der Defibrotidgruppe auf, zum Auftreten der GvHD in der Kontrollgruppe 
wurden keine Angaben gemacht. 
Die Studien wiesen verschiedene Einschränkungen auf: Unklare Follow-up 
Zeitpunkte, unklare Begleitmedikationen und fehlende Daten bezüglich Pa-
tientencharakteristika und deren Unterschiede zu Studienbeginn. Weitere 
Einschränkungen bezüglich der Studienqualität ergaben sich in zwei Studien 
durch die geringe Anzahl an PatientInnen und den Vergleich mit historischen 
Kontrollgruppen. 
unterschiedliche 







RCT mit 356 
paediatrischen 
PatientInnen mit 
Risikofaktoren für VOD 
 














in beiden Gruppen 
Einschränkungen  





Defibrotide for the treatment and prophylaxis of hepatic veno-occlusive disease 
16 LBI-HTA | 2015 
In den beiden historisch kontrollierten Studien wurden keine exakten Daten 
zum Auftreten von Nebenwirkungen genannt. Ergebnisse des RCT zeigten 
das Auftreten von Nebenwirkungen in 87–88 % der PatientInnen, 37 % hat-
ten schwerwiegende Nebenwirkungen. Allerdings wurden Nebenwirkungen, 
welche im Zusammenhang mit der Behandlung standen, bei nur 6 % der De-
fibrotidgruppe im Vergleich zu 4 % der Kontrollgruppe ohne Prophylaxe be-
obachtet. Schwerwiegende (Grad 3) mit der Behandlung in Zusammenhang 
stehende Nebenwirkungen traten bei 2 % der PatientInnen der Defibrotid-
gruppe und 3 % der PatientInnen der Kontrollgruppe auf. Die mit der Be-
handlung in Zusammenhang stehen Nebenwirkungen wurden gemessen, nach-
dem PatientInnen beider Studiengruppen bei Auftreten von VOD Defibro-
tid zur Behandlung erhalten hatten.  
Therapie von VOD 
Für die Beurteilung der Wirksamkeit von Defibrotid für die Therapie der 
hepatischen VOD konnten keine komparativen Studien gefunden werden. Als 
beste verfügbare Evidenz wurden eine prospektive Fall-Serie und eine rand-
omisierte Dosisfindungsstudie inkludiert. Insgesamt wurden 239 PatientIn-
nen (Erwachsene und Kinder), die sich einer HSCT unterzogen hatten und 
bei welchen eine hepatische VOD klinisch diagnostiziert wurde, inkludiert. 
Die PatientInnen waren im Mittel 34–35 Jahre alt (das Alter variierte zwi-
schen 0 und 63 Jahren). 68–87 % der PatientInnen hatten allogene Trans-
plantate, 42–53 % vor der HSCT Busulfan und 75–80 % Cyclophosphamide 
erhalten. 33–46 % der PatientInnen hatten sich einer Ganzkörperbestrahlung 
unterzogen. 
In beiden Publikationen wurden ähnliche Raten der Gesamtsterblichkeit (an 
Tag 100) gemessen (58–65 %). Die krankheitsspezifische Mortalität an Tag 
100 wurde nur in der Dosierungsfindungsstudie gemessen (28–29 %). Ein 
komplettes Ansprechen auf die Defibrotid Therapie war bei 36–46 % der Pa-
tientInnen zu beobachten. 
Nebenwirkungen wurden in der Dosierungsfindungsstudie beschrieben, hier 
waren insgesamt 97 % aller PatientInnen von Nebenwirkungen betroffen, wo-
von 89 % Nebenwirkungen von Grad 3 oder 4 waren. Mit der Therapie in 
Verbindung stehende Nebenwirkungen traten allerdings bei nur 8 % aller 
Behandelten auf (7 % in der Gruppe mit geringerer Dosierung, 10 % in der 
Gruppe mit höherer Dosierung). Davon waren 3 % der Nebenwirkungen von 
Grad 3 oder 4. Blutungen (Grad 3–4), welche mit der Therapie in Verbindung 
standen wurden in 1 % der PatientInnen berichtet. Es gab keine mit der The-
rapie assoziierten Todesfälle. 
Laufende Studien 
Die Suche in entsprechenden Datenbanken (siehe Kapitel 10.5) zeigte, dass 
es derzeit zwei einarmige Studien über die Behandlung der VOD mit Defi-
brotid gibt. Eine weitere Studie (parallel, randomisiert) evaluiert die Wirk-
samkeit und Sicherheit von Defibrotid für die Prophylaxe von VOD.  
Kostenerstattung 
Derzeit ist Defibrotid nicht im Leistungskatalog des Österreichischen Ge-
sundheitsministeriums enthalten. Für die Therapie der VOD würden, aus-
gehend von einem durchschnittlichen Körpergewicht eines Erwachsenen von 
70 kg, pro Tag 1.750 mg Defibrotid benötigt werden (6,25 mg/kg alle 6 Stun-
den). Defibrotid ist in Einheiten zu je 200 mg erhältlich, diese kosten jeweils 
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€ 426. Für die Verabreichung von 1.750 mg Defibrotid würden 9 Einheiten 
benötigt werden und Behandlungskosten von € 3.834 pro Tag entstehen. Aus-
gehend von einer Behandlungsdauer von mindestens 21 Tagen würden sich 
die Kosten für einen Behandlungszyklus auf € 80.514 belaufen. 
Aufgrund der noch ungeklärten optimalen Anwendungsdauer von Defibrotid 
für die VOD Prophylaxe sind die genauen Kosten schwierig zu berechnen. Im 
inkludierten RCT wurden die PatientInnen der Interventionsgruppe, welche 
Defibrotid für die Prophylaxe der VOD erhielten, im Mittel 35 Tage lang 
(zwischen 4 und 71 Tagen) behandelt. Ausgehend von einer Behandlungs-
dauer der VOD Prophylaxe von 35 Tagen würden Kosten von € 134.190 ent-
stehen. 
Defibrotid wurde über viele Jahre „off-label“, für die Behandlung von Pati-
entInnen, welche im Rahmen einer Hochdosistherapie mit autologer oder 
allogener HSCT eine VOD entwickelten, verwendet. Die Substanz war unter 
dem Handelsnamen Prociclide® für die Behandlung der tiefen Beinvenen-
thrombose zugelassen, die Kosten beliefen sich auf etwa € 350 pro Behand-
lungszyklus. Im Kontext einer prospektiven Zulassungsstudie wurde Procic-
lide von Markt genommen. Als Defibrotid unter dem Handelsnamen Defi-
telio® für die Behandlung der VOD zugelassen wurde, war dies mit einer star-
ken Preissteigerung verbunden. 
 
Diskussion 
Derzeit ist die Evidenz für beide mögliche Indikationen von Defibrotid rar. 
Durch die Seltenheit der Erkrankung ist die Durchführung von RCTs – vor-
allem für die Therapie von VOD, schwierig. Aktuell werden zwei einarmige 
Studien zur Behandlung der VOD mit Defibrotid und eine weitere Studie 
(parallel, randomisiert,) zur Evaluierung der Wirksamkeit und Sicherheit von 
Defibrotid für die Prophylaxe der VOD durchgeführt. Durch den derzeit be-
stehenden Evidenzmangel bleiben einige Fragen unbeantwortet: 
 Optimale Dosierung/Dauer: In den inkludierten Studien wurden ver-
schiedene Dosierungen (zwischen 10 und 25 mg/kg/Tag für die Pro-
phylaxe und zwischen 10 und 60 mg/kg/Tag für die Therapie) verwen-
det. Das British Committee for Standards in Haematology und die 
British Society for Blood and Marrow Transplantation empfehlen De-
fibrotid für die in einer Dosierung von 6,25 mg/kg 4 mal täglich für 
Kinder und Erwachsene. Allerdings sind laut Guideline weitere Stu-
dien nötig, um die optimale Dosierung von Defibrotid zu ermitteln. 
Ebenfalls ungeklärt ist die optimale Dauer der Behandlung (in den in-
kludierten Studien waren die Behandlungszeiträume unterschiedlich 
lange). Für Defibrotid gibt es auch die Möglichkeit der oralen Verab-
reichung, diese wurde jedoch in keiner der inkludierten Studien an-
gewandt. Es bleibt unklar, ob die Art der Verabreichung Einfluss auf 
die Outcomes hat. 
 Diagnosestellung: in den inkludierten Studien wurden unterschiedliche 
Systeme (Baltimore- oder modifizierte Seattle-Kriterien) angewandt. 
Dadurch wird die Erkrankung bei betroffenen PatientInnen in unter-
schiedlichen Stadien diagnostiziert, dies kann zu Unterschieden hin-
sichtlich der Outcomes führen.  
 Prophylaxe versus Therapie: es ist fraglich, ob die Therapie mit Defi-
brotid der Prophylaxe vorgezogen werden sollte. Da jüngere Patien-
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Prophylaxe gerade in dieser Altersgruppe bessere Ergebnisse erzielt 
werden als mit der Therapie. Von Guidelines wird die Prophylaxe von 
VOD nur für HochrisikopatientInnen empfohlen. 
 Population: im inkludierten RCT wurde die Defibrotid Prophylaxe 
ausschließlich an Hochrisikopatienten unter 18 Jahren untersucht. Auf-
grund der mangelhaften Evidenzlage bleibt die Wirksamkeit von De-
fibrotid bei Erwachsenen und Kindern mit niedrigem VOD-Risiko un-
geklärt. 
 Neben dem Alter der PatientInnen wurden noch einige andere Risi-
kofaktoren für die Entwicklung der VOD festgestellt. Die Reduktion 
von Risikofaktoren und die Riskostratifikation sind daher Schlüssel-
faktoren um das Auftreten der VOD zu reduzieren. 
 Langzeitdaten: es gibt keine Langzeitdaten über die Sicherheit der 




Insgesamt ist die Qualität der Evidenz für die Wirksamkeit und Sicherheit 
von Defibrotid zur VOD Prophylaxe mit „sehr niedrig“ bis“ mäßig“ zu be-
werten. 
Obwohl es Hinweise darauf gibt, dass die Prophylaxe mittels Defibrotid die 
Inzidenz von VOD bei Kindern mit hohem VOD-Risiko reduziert, kann die 
Aufnahme eines Medikaments in den Leistungskatalog ohne entsprechende 
Zulassung für diese Indikation nicht empfohlen werden. 
Eine erneute Evaluierung bei Änderung des Zulassungsstatus wird empfohlen. 
Defibrotid für die Therapie von VOD 
Die Qualität der Evidenz für die Wirksamkeit und Sicherheit von Defibro-
tid für die Behandlung der VOD wurde mit „sehr niedrig“ eingestuft. 
Die derzeit verfügbare Evidenz ist nicht ausreichend um die Wirksamkeit 
und Sicherheit von Defibrotid zur Therapie der hepatischen VOD zu bele-
gen. Da die VOD aber eine lebensbedrohliche Erkrankung darstellt, für die 
es keine andere Therapie gibt, stellt Defibrotid für PatientInnen mit schwe-
rer VOD eine Therapieoption dar. Daher wird die Aufnahme in den Leis-
tungskatalog mit Einschränkungen empfohlen. 
Die Ermittlung von Risikofaktoren und, falls möglich, die Vermeidung von 
Faktoren welche die Entwicklung einer VOD begünstigen, sollte sichergestellt 
werden. In einem PatientInnenregister sollten Behandlungsresultate, vor al-
lem Langzeitdaten bezüglich der Sicherheit von Defibrotid gesammelt wer-
den. Sobald diese Daten verfügbar sind, ist eine erneute Evaluierung emp-
fohlen. Weiters wird die Beobachtung des Zulassungsstatus von Defibrotid 
empfohlen, Risikoteilungsvereinbarungen werden als notwendig erachtet. 
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1 Scope 
1.1 Research questions 
Is defibrotide for the prophylaxis of veno-occlusive disease (VOD) for pa-
tients undergoing haematopoietic stem cell transplantation in comparison to 
no prophylaxis, placebo or other experimental options in adult and paediat-
ric patients more effective and safe concerning overall and disease-specific 
mortality, incidence of VOD, quality of life and adverse events? 
Is defibrotide for the treatment of severe veno-occlusive disease (VOD) after 
oncologic therapy or after haematopoietic stem cell transplantation in com-
parison to no treatment, placebo or other experimental options in adult and 
paediatric patients more effective and safe concerning overall and disease-
specific mortality, resolution of VOD, quality of life and adverse events?  
 
 
1.2 Inclusion criteria 
Inclusion criteria for relevant studies are summarised in Table 1.2-1. 
Table 1.2-1: Inclusion criteria 
Population Prophylaxis 
Adult patients, adolescents, children and infants over one month of age undergoing 
allogeneic or autologous stem cell transplantation 
Treatment 
Adult patients, adolescents, children and infants over one month of age with severe 
hepatic VOD after oncologic therapy or after allogeneic or autologous stem cell 
transplantation 
MeSH terms: Hepatic veno-occlusive disease [C06.552.360], Haematopoietic Stem 
Cell Transplantation [E04.936.225.687.500]; Liver Diseases [C06.552] 
ICD: K76.5; I82.0, Z94.8 
Intervention Prophylaxis 
Defibrotide (Defitelio®) is administered intravenously at a dosage of 10–25 mg/kg/day.  
Treatment 
Defibrotide (Defitelio®) intravenously at a dosage of 25 mg/kg/day for a minimum of 
21 days and should be continued until the symptoms and signs of severe VOD resolve. 
MeSH terms: Platelet Aggregation Inhibitors [D27.505.954.502.780];  
Fibrinolytic Agents [D27.505.519.421.750] 
Control Prophylaxis 
 No prevention 
 Placebo 
 Other experimental agents for prophylaxis (e.g., ursodeoxycholic acid)  
Treatment 
 No therapy 
 Placebo 
 Other experimental agents for the treatment (e.g., methylprednisolone,  
N-acetylcystein) 
PICO questions 
inclusion criteria  
Defibrotide for the treatment and prophylaxis of hepatic veno-occlusive disease 
20 LBI-HTA | 2015 
Outcomes  
Efficacy Prophylaxis 
 Overall mortality  
 Disease-specific mortality 
 Incidence of VOD 
 Quality of life  
 Severity of VOD 
 Incidence of GVHD 
Treatment 
 Overall mortality 
 Disease-specific mortality 
 Resolution of VOD 
 Quality of life 
Safety  Severe adverse events 
 Treatment-related mortality 
Study design  
Efficacy Randomised controlled trials  
Prospective non-randomised controlled trials 
Safety Randomised controlled trials  
Prospective non-randomised controlled trials  
Any prospective study design 
 
 
1.3 Literature search 
The systematic literature search was conducted on the 30th of December, 2014 
in the following databases:  
 Medline via Ovid 
 Embase  
 The Cochrane Library 
 CRD (DARE, NHS-EED, HTA). 
Search filters were applied in Medline and Embase to limit the results to clin-
ical trials and systematic reviews. After deduplication, 151 citations overall 
were included. The specific search strategy employed can be found in the Ap-
pendix.  
The manufacturer (Gentium SpA) submitted seven publications of which two 
had already been identified by the systematic search, therefore resulting in 
five new citations. A Scopus search of two reference articles identified an ad-
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1.4 Flow chart study of selection 
Overall, 151 hits were identified. The references were screened by two inde-
pendent researchers. In case of disagreement, a third researcher was involved 
to solve the differences. The selection process is displayed in Figure 1.4-1: 
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2 Description and technical 
characteristics of technology 
2.1 Methods 
Research questions 
Element ID Research question 
Importance 
2 = critical 
1 = optional 
B0001a What is defibrotide? 2 
B0001b What is the comparator for the prophylaxis of VOD? 2 
B0001c What is the comparator for the treatment of VOD? 2 
A0020 For which indications has defibrotide received marketing authorisation? 2 
B0002 What is the claimed benefit of defibrotide in relation to the 
comparators? 
1 
B0004 Who administers defibrotide and the comparators and in what context 
and level of care are they provided? 
1 
B0009 What supplies are needed to use defibrotide and the comparators? 1 
A0021 What is the reimbursement status of defibrotide? 2 
 
Sources 
The basic search was used to answer most of the research questions. In addi-
tion, websites of the European Medicines Agency (EMA) and the U.S. Food 





Features of the technology and comparators 
B0001a – What is defibrotide? 
Defibrotide is a large, single-stranded deoxyribonucleotide. It is obtained from 
porcine intestinal mucosa and prepared by controlled depolymerisation of de-
oxyribonucleic acid (DNA) [1].  
While in vitro data supports a role for defibrotide in endothelial cell protec-
tion by antithrombotic, profibrinolytic and anti-inflammatory effects, there 
are no established pharmacodynamic effects in vivo [2, 3]. Thus, the precise 
mechanism of action still remains unknown. However, by interaction with 
various receptors (e.g., adenosine receptors A1 and A2) which are located on 
the vascular endothelium, the expression of certain adhesion molecules (e.g., 
intercellular adhesion molecule 1 [ICAM-1]) is reduced and thereby the influx 
of inflammatory mediators [3]. By this means, the narrowing of hepatic sinus-
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in partial revascularisation; it activates the fibrinolytic system (increases the 
function of tissue plasminogen activator (t-PA), decreases the plasminogen 
activator inhibitor-1), reduces the activation of the extrinsic coagulation path-
way and exerts anti-inflammatory effects by stimulating prostaglandin pro-
duction [3]. Through the combination of these effects, defibrotide is thought 
to help maintain the hepatic sinusoidal integrity. 
In terms of graft-versus-host disease (GVHD), defibrotide is expected to work 
by reducing formation of blood clots and increasing their breakdown in the 
blood; furthermore it may protect the cells lining blood vessels, which are 
damaged in patients undergoing stem-cell transplantation [4]. 
 
B0001b – What is the comparator for the prophylaxis of VOD? 
No standard therapy is available for the prophylaxis of VOD in transplant 
recipients, but several experimental agents have been tested, including hep-
arin, low-dose heparin, danaparoid, ursodeoxycholic acid or glutamine [5]. 
Of these, the clinical use of two agents, i.e., ursodeoxycholic acid (UCDA) and 
low-dose heparin, is supported by randomised trials. They are applied depend-
ing on the type of hematopoietic stem cell transplantation (HSCT) regimen [6]: 
 UDCA for patients undergoing allogeneic HSCT. It is administered 
at a daily dosage of 12 mg/kg (in two doses) from the day preceding 
the preparative regimen and is continued for the first three months of 
transplantation. 
 Low-dose heparin for patients undergoing autologous HSCT. Patients 
receive heparin at a dosage of 100 units/kg per day (continuous intra-
venous infusion) from the first day of the preparative regimen until 
hematopoietic engraftment. 
 
B0001c – What is the comparator for the treatment of VOD? 
For the treatment of VOD no standard therapy is available. The mainstay of 
VOD therapy is supportive care, including fluid restriction and diuretics, and 
avoidance of hepatotoxic medications [7]. Other agents which have been used 
in clinical practice include tissue plasminogen activator (t-PA), N-acetylcyste-
ine or methylprednisolone [8]. 
 
A0020 – For which indications has defibrotide received  
marketing authorisation? 
In 2004, defibrotide received orphan designation by the European Commis-
sion for the treatment of hepatic VOD. In November 2013, the EMA granted 
orphan designation for defibrotide for the prevention of GVHD [9]. 
In September 2013, the European Medicines Agency (EMA) granted market-
ing authorisation for Defitelio® “for the treatment of severe VOD also known 
as sinusoidal obstructive syndrome (SOS) in hematopoietic stem-cell trans-
plantation (HSCT) therapy” [1].  
Prior to this decision, EMA’s Committee for Medicinal Products for Human 
Use (CHPM) adopted a negative opinion concerning the licensing of Defite-
lio® for the treatment and prophylaxis of VOD in March 2013. The Committee 
noted for both indications that the evidence provided by the manufacturer 
suffered from methodological flaws. Another concern which subsequently led 
to a refusal of market authorisation was the lack of data for patients with 
comprised kidney function [10].  
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The manufacturer requested a re-examination restricting the indications to 
the treatment of patients with severe VOD and the prevention of VOD only 
in patients at high risk. The manufacturer withdrew their application for pro-
phylaxis prior to a final decision of the CHMP, which ultimately led to the 
market authorisation for the treatment of severe VOD only [10]. However, the 
market authorisation was granted “under exceptional circumstances” and 
Defitelio® is under additional monitoring, meaning that it is monitored even 
more intensively than other medicines [11]. 
Defitelio® is available in Germany, Italy (under special law 648/96), France, 
the UK, Sweden, the Netherlands, Denmark, Norway, Finland and, since the 
24th of March, 2014, in Austria [12]. 
In the U.S., Defitelio® has not been approved by the FDA, but it is available 
under an expanded-access protocol [13]. This protocol, sometimes also la-
belled “compassionate use”, is intended for investigational medical products 
for serious diseases or conditions for which no comparable or satisfactory al-
ternative therapy exists. If patients cannot be enrolled into clinical trials or if 
there are no ongoing trials, patients can get access to investigational products 
even outside of trials. Defibrotide also received orphan drug designation from 
the FDA for the treatment of hepatic VOD (in 2003) and for the prevention 
of hepatic VOD (in 2007) [14]. 
 
B0002 – What is the claimed benefit of defibrotide  
in relation to the comparators? 
For the prevention of VOD, no approved drugs are available. Since VOD ther-
apy is unsuccessful in most instances, routine prophylactic therapies are com-
monly administered in transplant centres to avoid the occurrence of VOD. 
However, in the absence of standard therapies, regimens administered vary 
considerably across centres [5]. Defibrotide would thus be a new option for 
the prophylaxis of VOD.  
VOD is a potentially life-threatening disease with a high mortality. Of the 
patients receiving HSCT, about 70% develop VOD, resulting in death in 
about 84% of severe cases despite therapy [7]. Even though several agents 
have been used for the treatment of VOD, defibrotide is currently the only 
approved drug for it. Defibrotide is thus a new treatment option for VOD. 
 
Administration, investments, personnel and tools required  
to use the technology and the comparators 
B0004 – Who administers defibrotide and the comparators  
and in what context and level of care are they provided? 
Defibrotide and other available pharmaceutical therapeutic options have to 
be administered by specialised physicians experienced in the diagnosis and 
treatment of the complications of HSCT [2]. Defibrotide treatment requires 
in-patient care at university hospitals or transplant centres. In the case of se-
vere VOD development with progression to multi-organ failure (MOF), affect-
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B0009 – What supplies are needed to use defibrotide  
and the comparators? 
Defibrotide is marketed under the name Defitelio®. It is available in single-use 
glass vials of 2.5 mL. One mL contains 80 mg of defibrotide, corresponding 
to 200 mg in one 2.5 mL vial [2]. Defibrotide has to be diluted with 5% glu-
cose solution or sodium chloride 9 mg/mL (0.9%) solution and is subsequent-
ly administered by an intravenous infusion over two hours. Contraindications 
listed are hypersensitivity for defibrotide or any of the excipients (sodium cit-
rate, dihydrate, hydrochloric acid, sodium hydroxide, water for injection) and 
the concomitant use of thrombolytic therapy [2]. 
For the treatment of patients with severe VOD, defibrotide plus supportive 
care can be administered [6, 8], which is indicated in adults, adolescents, 
children and infants over one month of age. Defibrotide is administered at a 
dosage of 6.25 mg/kg body weight every six hours (25 mg/kg/day) i.v. for a 
minimum of 21 days and should be continued until the symptoms and signs 
of severe VOD resolve. The dosage for children (from one month of age up to 
18 years) is the same as for adults. It is not recommended to administer dos-
es above 25 mg/kg per day due to limited efficacy and safety data on doses 
above this level [2]. 
For the prophylaxis of VOD, the recommended dosage is 6.25 mg/kg i.v. four 
times daily in children undergoing allogeneic SCT with the following risk 
factors: pre-existing hepatic disease, second myeloablative transplant, alloge-
neic transplant for leukaemia beyond second relapse, conditioning with busul-
fan-containing regimens, prior treatment with gemtuzumab ozogamicin, di-
agnosis of primary haemophagocytic lymphohistiocytosis, adrenoleukodystro-
phy or osteopetrosis. For adults under the same conditions, the suggested dos-
age to prevent VOD is also 6.25 mg/kg i.v. four times daily [8]. 
The administration of defibrotide requires an intravenous infusion set and 
sodium chloride 9 mg/mL (0.9%) or 5% glucose solution for dilution prior to 
use. An intravenous infusion set is required for heparin administration, where-
as UDCA is administered orally. 
 
Regulatory & reimbursement status  
A0021 – What is the reimbursement status of defibrotide? 
According to the submission documents received from the Ministry of Health 
(MoH), defibrotide is currently not included in the Austrian catalogue of ben-
efits. Assuming an average body weight of 70 kg for adults, 1,750 mg de-
fibrotide are needed per day (i.e., 6.25 mg/kg every six hours). Defibrotide is 
available in vials containing 200 mg, costing € 426. For the administration of 
1,750 mg, nine vials would be needed, corresponding to daily treatment costs 
of € 3,834. Assuming a treatment duration for a minimum of 21 days, costs 
of € 80,514 would occur.  
The costs for defibrotide for VOD prophylaxis are hard to calculate due to 
the unclear duration of administration. In the included RCT [15] patients who 
were allocated to the intervention group received defibrotide for VOD pro-
phylaxis for a median of 35 days (range 4–71). Thus, assuming a duration of 
35 days for VOD prophylaxis, costs of € 134,190 would occur. According to 
information submitted by the applicants, defibrotide was used in Austria off-
label for over ten years in patients who developed VOD after high-dose chemo-
therapies with consecutive autologous or allogeneic HSCT. For many years, 
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defibrotide was available as Prociclide® (approved for the treatment of deep 
vein thrombosis) for approximately € 350 per treatment cycle. Later, the mar-
keting authorisation was withdrawn in the context of a prospective approval 
study (indication: VOD). The EMA approval (under exceptional circumstanc-
es) of Defitelio® for the treatment of VOD was associated with a substantial 
price increase of the drug.  
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3 Health problem and current use 
3.1 Methods 
Research questions  
Element ID Research question 
Importance 
2 = critical  
1 = optional 
A0002 What is VOD? 2 
A0001 For which health conditions and for what purposes is defibrotide used? 2 
A0003 What are the known risk factors for hepatic VOD? 2 
A0004 What is the natural course of VOD? 2 
A0024 How is VOD currently diagnosed according to published guidelines and 
in practice? 
2 
A0025a How is VOD prophylaxis currently managed according to published 
guidelines and in published guidelines and in practice? 
2 
A0025b How is VOD therapy currently managed according to published 
guidelines and in practice? 
2 
A0007 What is the target population in this assessment? 2 
A0023 How many people belong to the target population? 2 
A0011 How much is defibrotide utilised? 1 
 
Sources 




Overview of the disease or health condition 
A0002 – What is VOD?  
VOD, also termed hepatic sinusoidal obstruction syndrome (SOS), most often 
occurs as a result of a conditioning treatment administered prior to HSCT 
[8]. HSCT is indicated in patients suffering from malignant but also non-
malignant diseases such as thalassaemia who have received chemotherapy 
that has destroyed, besides malignant cells, normal blood-forming cells in 
the bone marrow. By transplanting haematopoietic stem cells, the ability of 
the patient to produce blood cells should be restored. Allogeneic transplants 
can be distinguished from autologous transplants. For allogeneic HSCT, cells 
are harvested from a donor other than the transplant recipient, whereas for 
autologous transplants the patient’s own cells are used [16]. 
Allogeneic HSCT replaces the affected immune system and is used to to ex-
ploit the graft versus tumour effect of allogeneic cells [17]. For the condition-
ing therapy, traditional myeloablative conditioning regimens, reduced-inten-
sity- and non-myeloablative regimens are available [18], regimens with a re-
duced incidence of VOD. 
VOD often caused by 
conditioning treatment 
prior to HSCT 
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Previous expositions to chemotherapeutic agents or high-dose radiation ther-
apy, ingestion of alkaloid toxins or liver transplantation are less common 
causes for VOD [19]. 
Hepatic sinusoidal endothelial cell lesions are deemed to be the primary cause 
of VOD, leading to the non-thrombotic occlusion of the hepatic veins with 
concentric subendothelial thickening associated with oedema and fibrosis 
[20]. VOD occurs most commonly within the first three weeks after perform-
ing HSCT, but it can generally occur at any time after HSCT treatment [19]. 
Characteristic symptoms of VOD are painful hepatomegaly, right upper quad-
rant pain, jaundice and ascites [19]. Functional renal insufficiency is com-
mon and coagulopathy and hepatic encephalopathy may indicate hepatic in-
sufficiency [20]. 
VOD is classified as a rare disease affecting children and adults [20]. The in-
cidence between studies varies widely, depending on the type of transplant, 
the applied conditioning regimen and the diagnostic criterions used.  
The GVHD is a further potential complication occurring after haematopoietic 
cell transplant. The disease develops when immune cells transplanted from 
a non-identical donor recognise the transplant recipient as foreign, thereby 
initiating an immune reaction that causes disease in the transplant recipient 
[21]. 
 
A0001 – For which health conditions and for what purposes  
is Defitelio® used? 
In Europe, the licensed indication of defibrotide is: 
 the treatment of severe hepatic VOD in HSCT in adults, adolescents, 
children and infants over one month of age.  
In addition, based on the submission documents received, coverage in the 
catalogue of benefits is also sought: 
 for the treatment of VOD after chemotherapy, 
 for the prophylaxis of VOD in patients undergoing HSCT. 
 
A0003 – What are the known risk factors for hepatic VOD? 
Risk factors for developing VOD include: 
 pre-existing liver disease (characterised by elevation of the liver 
enzyme aspartate aminotransferase) 
 type of conditioning regimen (higher when cyclophosphamide or 
high doses of radiation are used)  
 source of graft (allogeneic greater than autologous) 
 age of patients (children <7 years are more often affected) 
 a poor performance status at baseline  
 prior abdominal radiation therapy, 
 diagnosis of osteopetrosis, primary haemophagocytic lymphocytosis 
or adrenoleukodystrophy [13]. 
 graft-versus-host disease (GVHD) prophylaxis regimens [22]. 
Depending on the absence or presence of one or more of these risk factors, 
patients at high risk for developing VOD are identified [8].  
hepatic sinusoidal 
endothelial cell lesion 
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A0004 – What is the natural course of VOD? 
The natural course of VOD depends on the severity of the disease. Severity is 
based on clinical features which can only be assigned retrospectively [8]. No 
commonly accepted criteria are used for assessing the severity of VOD [23]. 
Some authors suggest that patients with mild VOD can be defined as those 
who do not require therapy; patients who need best supportive care to allevi-
ate pain from hepatomegaly are considered as having had moderate VOD, 
whereas patients who die from VOD or with illness that persists >100-day 
post-HSCT are considered to have had severe VOD [8, 19].  
Due to the lack of unified criteria, the evolution of MOF has been proposed 
as a better predictor of severity and outcome [24]. Accordingly, in the Euro-
pean Public Assessment Report by the EMA, severe disease is defined as VOD 
in the presence of multi-organ failure (MOF), pulmonary dysfunction (with 
an oxygen requirement with an oxygen saturation of <90% on room air and/ 
or ventilator dependence), and/or renal dysfunction (defined as the doubling 
of baseline creatinine and/or dialysis dependence), and/or encephalopathy.  
Of the patients developing VOD, there are indications that about one-quarter 
of those with VOD progress to severe disease [25]. The mortality rate from 
severe VOD has been reported at 84.3% when treated with supportive care 
alone [6, 24], in comparison to about 20% for patients with moderate VOD 
[13]. Patients usually do not die due to VOD, but rather of liver failure. Pro-
gressive MOF with consecutive lethal renal and cardiopulmonary complica-
tions are typically the main causes of death [1]. As predictions for develop-
ing severe VOD, the early development of jaundice and weight gain after 
transplant and MOF are mentioned.  
 
Current clinical management of the disease or health condition 
A0024 – How is VOD currently diagnosed according to published 
guidelines and in practice? 
For the diagnosis of VOD, two systems based on clinical diagnostic criteria 
are established [19]: 
 According to the modified Seattle criteria, VOD is diagnosed when 
(within 20 days of HCT) two or more of the following occur: 
 Serum bilirubin >2 mg/dL 
 Hepatomegaly or right upper quadrant pain 
 Weight gain (>2 percent of baseline body weight) caused  
by fluid accumulation. 
 The Baltimore criteria define VOD by bilirubin concentration greater 
than 2 mg/dL within 21 days of HCT and the occurrence of two or more 
of the following: 
 Hepatomegaly 
 Ascites 
 Weight gain >5%, measured against body weight before HCT. 
For the purpose of differential diagnosis, other diseases leading to hepatic 
failure, e.g., Budd-Chiari syndrome, acute GVHD, hepatic infections and drug 
toxicity, need to be excluded by Doppler ultrasonography and serologies. Both 
VOD and acute GVHD can cause abdominal pain and a rising serum biliru-
bin. The most definitive method to distinguish the diseases is biopsy, which 
is rarely performed due to the bleeding risk [19]. 
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These clinical criteria are used for assessing the severity of VOD, but they can 
only be assigned retrospectively. When patients are followed up for the first 
100 days after HSCT, but do not require therapy despite liver biochemical 
abnormalities and other clinical features of the disease, they are considered 
to have mild VOD. Patients requiring sodium restriction and diuretics for 
fluid retention and/or medications to alleviate pain from hepatomegaly are 
considered to have moderate VOD, whereas patients who die within 100 days 
post-transplant or have persistent hepatic dysfunction lasting more than 100 
days have severe VOD [8]. 
 
A0025a – How is VOD prophylaxis currently managed according  
to published guidelines and in practice? 
No standard management scheme exists for preventing the occurrence of 
VOD in patients receiving chemotherapy and HSCT. An assessment of risk 
factors for individual patients, which is aimed at reducing the likelihood of 
developing VOD, is currently recommended. For example, the administra-
tion of a reduced intensity conditioning treatment or treatment with treosul-
fan instead of a busulfan conditioning therapy have been shown to reduce 
the risk of VOD especially in paediatric patients [8].  
Even though defibrotide can be administered as a prophylaxis for all patients 
undergoing HSCT, another option is to restrict defibrotide prophylaxis to 
those patients at a particularly high risk of developing VOD [5, 8]. The Brit-
ish Committee for Standards in Haematology and the British Society for Blood 
and Marrow Transplantation recommend the regimen for children (level of 
recommendation is 1A = strong recommendation with high quality of evi-
dence) and for adults (level of recommendation is 2B = weak recommenda-
tion based on moderate quality of evidence) undergoing allogeneic stem cell 
transplantation who additionally have any of the following risk factors: pre-
existing hepatic disease, second myeloablative transplant, allogeneic trans-
plant for leukaemia beyond second relapse, conditioning with busulfan-con-
taining regimens, prior treatment with gemtuzumab ozogamicin, diagnosis 
of primary hematophagocytic lymphohistiocytosis, adrenoleucodystrophy or 
osteopetrosis [8].  
Besides defibrotide, the guidelines suggest only UDCA for the prophylaxis of 
VOD [8].  
 
A0025b – How is VOD therapy currently managed according  
to published guidelines and in practice? 
Regardless of the severity of the disease, a key factor in managing affected 
patients is supportive care focussed on fluid balance and maintaining intra-
vascular volume and renal perfusion while limiting third space fluid collec-
tion. Substances which potentially induce liver injury need to be avoided [6]. 
In patients with mild or moderate VOD, supportive care might be a sufficient 
therapy. Nevertheless, it is important to reassess severity every day to recog-
nise changes [6]. 
The British Committee for Standards in Haematology and the British Socie-
ty for Blood and Marrow Transplantation recommends the use of defibrotide 
in the treatment of VOD in adults and children (level of recommendation is 
1B = strong recommendation with moderate quality of evidence). Methyl-
prednisolone may be considered for use in the treatment of VOD with the 
appropriate caveats of caution regarding infection [8]. Experimental treat-
severity can only be 
assessed retrospectively 
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ment approaches recommended within this guideline are surgical treatment 




A0007 – What is the target population in this assessment? 
The target population in this assessment consists of adults, adolescents, chil-
dren and infants over one month of age for the treatment of severe VOD and 
for the prophylaxis of VOD.  
 
A0023 – How many people belong to the target population?  
Since VOD is an orphan disease, the number of patients affected is low; no 
more than five in 10,000 people in the European Union are affected [2]. With 
an overall population of 8.5 million in Austria, a maximum of 4,250 people 
would be affected by VOD.  
For patients undergoing HSCT, varying estimates for the frequency of VOD 
are given. One study calculated the overall mean incidence of VOD in pa-
tients undergoing HSCT across 135 studies performed between 1979 and 2007. 
The mean incidence was 13.7% (with absolute values ranging from 0 to 62.3%) 
across age groups with differences for adults and children; however, in the 
majority of studies (130/135) the variation in incidence ranged from 0 to 40%. 
Only five studies reported an incidence of VOD over 40%; all of them in-
cluded high-risk patient groups. The mortality rate from severe VOD was 
84.3%; both prevention studies and studies evaluating the treatment of VOD 
were included in this review [24]. A mean incidence of about 25% was re-
ported for children [26]. Lee et al. reported an incidence of VOD in the pae-
diatric transplant population ranging from 11–31%, with an associated death 
rate of up to 50% [27]. Of patients developing VOD, there are indications 
that about one-quarter of those with VOD progress to severe disease [28]. 
Estimating the number of patients who would qualify for VOD prophylaxis 
is more difficult, since it depends on the qualification criteria: i.e., whether 
every transplant patient may be treated with prophylaxis or the treatment is 
restricted to patients at high risk only.  
Estimates of the incidence of VOD will also depend on the set of diagnostic 
criteria used (see also A0024 and C0007). 
 
A0011 – How much are the technologies utilised? 
Based on the submission files received from the MoH, the actual number of 
current interventions delivered ranged from 60–380, depending on the size 
of the hospital submitting the application. The indicated number of estimat-
ed annual utilisation rates ranged from 500–5,000. According to information 
submitted by the applicants, defibrotide was used off-label for over ten years 
in patients who developed VOD after high-dose chemotherapies with consec-
utive autologous or allogeneic SCT. 
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4 Clinical effectiveness 
4.1 Methods 
Research questions 
Element ID Research question 
Importance 
2 = critical  
1 = optional 
D0001a What is the expected beneficial effect of defibrotide prophylaxis of 
VOD on overall mortality? 
2 
D0001b What is the expected beneficial effect of defibrotide treatment of VOD 
on overall mortality? 
2 
D0001c What is the expected beneficial effect of defibrotide prophylaxis on 
disease-specific mortality? 
2 
D0001c What is the expected beneficial effect of defibrotide treatment on 
disease-specific mortality? 
2 
D0005a  How does defibrotide prophylaxis affect the incidence of VOD? 2 
D0005b How does defibrotide therapy affect the resolution of VOD? 2 
D0005c How does defibrotide therapy affect the severity of VOD? 2 
D0005d How does defibrotide prophylaxis affect the incidence of GVHD? 2 
D0012 What is the effect of defibrotide on generic health-related quality of life? 1 
D0013 What is the effect of defibrotide on disease-specific quality of life? 1 
 
The following crucial outcomes for prophylaxis with defibrotide were used as 
evidence to derive a recommendation: 
 Overall mortality 
 Disease-specific mortality 
 Incidence of VOD 
 Quality of life. 
The following crucial outcomes for defibrotide treatment were used as  
evidence to derive a recommendation: 
 Overall mortality 
 Disease-specific mortality 
 Resolution of VOD 
 Quality of life. 
Since VOD is a life-threatening disease, the ultimate aim of prophylaxis or 
treatment with defibrotide is to prolong life. Health-related quality of life is 
a relevant secondary outcome measure [29]. Avoidance of the occurrence of 
VOD is also deemed to be of critical relevance for the assessment of the ef-
fectiveness of a prophylactic regimen. For therapy with the agent, the resolu-
tion of VOD goes hand in hand with a reduced morbidity; therefore, it can 
also be considered as an outcome relevant for patients.  
 
ultimate aim for 
treatment and 
prophylaxis is 
prolongation of life 
Defibrotide for the treatment and prophylaxis of hepatic veno-occlusive disease 
36 LBI-HTA | 2015 
Sources 
The information for this chapter was retrieved by a systematic literature 
search in four databases: Medline via Ovid, Embase, The Cochrane Library 
and CRD (DARE, NHS-EED, HTA), complemented by a Scopus search. 
 
Analysis 
To evaluate the effectiveness of defibrotide for the treatment and prevention 
of VOD, data from the included studies were extracted in evidence tables pro-
vided in the Appendix (A1-1, A1-2 and A1-3). No further analysis was per-
formed. The internal validity of the included studies was assessed in Tables 
A2-1, A2-2 and A2-3 based on criteria used in the Internal Manual of the LBI-
HTA [30] and in the Risk of Bias tool for randomised controlled trials from 
the Cochrane Collaboration [31] as provided in the Guidelines of EUnetHTA 
[32]. The strength of evidence of effectiveness was assessed according to the 
GRADE methodology [33].  
 
Synthesis 
The research questions were answered in plain text format, based on the re-





Prophylaxis of VOD 
For assessing the effectiveness of prophylaxis of VOD with defibrotide, three 
studies overall were included [15, 34, 35]. The studies comprised one ran-
domised controlled trial (RCT) [15] and two historically controlled prospec-
tive studies [34, 35]. Overall, 563 patients, all undergoing HSCT, were in-
cluded. In two trials [15, 34] the study population consisted of children and 
adolescents (≤18 years), whereas the third publication did not apply any age 
limit, resulting in a median age of about 37 years [35]. In contrast to the non-
randomised studies, the presence of at least one risk factor for VOD deter-
mined eligibility for the RCT. Most of the HSCT were allogeneic transplants 
(53–100%), a conditioning treatment containing busulfan was used in 15–56% 
and a pre-existing liver disease was present in 12–34% [15, 34, 35]. Different 
risk groups were formed in the two non-randomised studies based on vary-
ing criteria (see Table A1-2). 
Overall, 279 patients had been treated with defibrotide. The dosage of defib-
rotide ranged from 10 mg [35] over 20 mg [34] to 25 mg/kg/day [15] for 20–30 
days after transplantation. When patients developed a VOD, dosage was ei-
ther increased to 40–60 mg/kg/day [34] or patients who had previously not 
received defibrotide were treated for VOD with the same dosage as the inter-
vention group [15].  
 
3 prevention studies 
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The 284 patients who served as controls had received no defibrotide for VOD 
prophylaxis (n=228), but received the same concomitant therapies like the 
intervention group, which consisted either of low-dose heparin [35], UDCA 
[15] or, in one study, patients received UDCA and tinziparin for those con-
sidered as high risk [34] as VOD prophylaxis (n=56). 
VOD assessment was done in two studies [15, 34] according to the modified 
Seattle criteria and, in the third study, based on the Baltimore criteria [35]. 
Follow-up, if reported, ranged from 180 days [15] to 57 months [35]. 
Study characteristics and results of included studies are displayed in Tables 
A1-1, and A1-2. 
Treatment of VOD 
No prospective comparative studies were identified for the assessment of ef-
fectiveness. As best available evidence, two studies were included: one pro-
spective case series [36] and one randomised dose-finding study [37]. Due to 
the comparison of two different dosages of defibrotide, the comparator was 
not relevant for the study question and the study was therefore treated as sin-
gle-arm study. 
Overall, 239 adult and paediatric patients who had undergone HSCT and were 
clinically diagnosed with hepatic VOD were included. Patients had a median 
age of 34–35 years, with a wide age range from 0 to 63 years. Most of the trans-
plants were allogeneic (68–87%); previously, 42–53% of patients had been 
treated with busulfan; in 75–80% of patients the conditioning regimen con-
sisted of cyclophosphamide. 33–46% of patients had undergone total body 
irradiation.  
In the dose-finding trial, the clinical diagnosis of VOD was defined as the 
presence of jaundice (total serum bilirubin ≥2 mg/dL) and at least two asso-
ciated signs (ascites, weight gain >5% from baseline, hepatomegaly or right 
upper quadrant pain, by day + 35 post HSCT + US to confirm diagnosis) 
[37]. In the prospective case series, patients were considered having severe 
VOD when jaundice (bilirubin ≥34.2 μM), hepatomegaly and/or right upper 
quadrant pain, and ≥5% weight gain from admission, with or without asci-
tes were diagnosed. Patients who met at least two criteria and had a liver bi-
opsy and patients not addressed by the Bearman model were eligible if VOD 
was considered their major clinical problem and organ failure was present in 
at least one other organ system. Patients with a concurrent, potential con-
founding cause of liver dysfunction such as GVHD or inconsistent findings 
evident on ultrasound imaging were required to have biopsy-proven VOD to 
be considered eligible [36]. According to the Bearman model, the risk of de-
veloping severe VOD is related to the degree of weight gain, the rise in bili-
rubin and the day of transplant when these changes occur [8]. 
Overall, 239 patients were treated with defibrotide. In the dose-finding trial 
[37], the starting dose was 10 mg/kg, increased to 25 mg/kg/day in arm A, and 
to 40 mg/kg/day in arm B for a minimum of 14 days or until the achieve-
ment of complete remission, or until the progression of VOD, unacceptable 
toxicity (recurrent grade 3/4 adverse events (AEs) considered likely or defi-
nitely related to defibrotide), or comorbidities precluded further treatment. 
In the prospective case series [36], patients received defibrotide 10 mg/kg/day 
as four divided doses; the dose was increased incrementally to a maximum 
potential total daily dose of 60 mg/kg for a minimum of 14 days. 
Study characteristics and results of included studies are displayed in Table 
A1-3. 
2 studies included  
for assessing defibrotide 
for VOD treatment with 
239 patients overall 
total daily dosages from 
10–60 mg/kg 
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Mortality 
D0001a – What is the expected beneficial effect  
of defibrotide prophylaxis of VOD on overall mortality? 
All three studies assessed overall mortality at 100 days after transplant. In 
the defibrotide groups 0–10% patients died in comparison to 4–19% in the 
control groups. The RCT did not find a statistically significant difference 
between the two groups (both 10%), but this outcome may have been biased 
due to the administration of therapeutic defibrotide after the development 
of VOD in both groups of the trial (I 13% vs. C 20%). In addition, 31% of 
patients in the intervention group and 32% in the control group respectively 
received concomitant UDCA. Chalandon et al. also calculated the statistical 
significance between their groups and showed no significantly reduced mor-
tality rate for defibrotide (p=.07).  
 
D0001b – What is the expected beneficial effect  
of defibrotide treatment of VOD on overall mortality? 
In the dose-finding RCT and the prospective case series, overall mortality on 
day +100 was 58% to 65% [36, 37].  
 
D0001c – What is the expected beneficial effect of defibrotide 
prophylaxis on disease-specific mortality? 
Two prophylaxis studies presented results for disease-specific mortality for 
460 patients overall [15, 35]. 0–2% in the intervention groups and 6% in the 
control group respectively died due to VOD. With 2% in the defibrotide group 
and with 6% in the no prophylaxis group, the RCT found no statistically 
significant difference. However, these numbers may have been compromised 
due to defibrotide therapy after VOD occurrence in both groups. The second 
study did not calculate statistical significance [35]. 
 
D0001d – What is the expected beneficial effect  
of defibrotide treatment on disease-specific mortality? 
Results on disease-specific mortality + 100 days were provided only in the 




D0005a – How does defibrotide prophylaxis affect the incidence of VOD? 
All three prophylaxis studies calculated the incidence of VOD, ranging from 
0–12% in the intervention groups to 7–20% in the control groups. These re-
sults have to be interpreted against the background of usage of different cri-
teria for the diagnosis of VOD. The modified Seattle criteria were used in 
two studies [15, 34], whereas the third used the Baltimore criteria [35]. The 
latter criteria are considered more restrictive, resulting in fewer cases diag-
nosed, but usually at a later stage with more severe cases of VOD. Abdominal 
ultrasound + Doppler tests were used in all studies to confirm diagnosis. 
VOD incidence (assessed according to the modified Seattle criteria) was the 
primary outcome in the RCT. A cumulative risk approach, which took death 
not related to VOD, study discontinuation due to an AE or receipt of a sec-
overall mortality:  
no significant difference 




no significant difference 
shown in the RCT 
incidence of VOD: 
different diagnosis 
criteria used among 
studies 
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ond transplant into account, was used. A risk difference of -7.7% was found 
for this analysis, closely reaching statistical significance with a p-value of 
.0488. According to the Kaplan-Meier method, p was .050.  
A second study calculated the difference of incidence and found, with 0% in 
the intervention group and with 19% in the historical control group receiving 
heparin, a significant difference [35]. However, it is not clearly evident when 
the different incidences (0% vs. 19%) were measured. Of note, the dosage of 
defibrotide was 10 mg/kg/day for patients considered at standard risk (i.e., 
acute leukaemia in first complete remission, chronic myeloid leukaemia in 
chronic phase 1) and 25 mg/kg/day for all others considered at high risk.  
 
D0005b – How does defibrotide therapy affect the resolution of VOD? 
VOD resolution (= complete response, CR) was achieved by 36% of patients 
in the prospective case series (CR defined as evidence of improvement in 
VOD-related symptoms and concurrent MOF, and a concomitant or subse-
quent decrease in bilirubin to less than 34.2 μM) and by 46% of patients in 
the dose-finding trial (CR defined as total serum bilirubin <2 mg/dL after 
initiation of defibrotide with resolution of VOD-related MOF). 
 
D0005c – How does defibrotide therapy affect the severity of VOD? 
Corbacioglu et al. [38] reported an incidence of MOF on day + 100 of 32% 
(bilirubin not elevated) vs. 60% (elevated bilirubin >2 mg/dL) of patients 
(p=.0383). Data for VOD severity unrelated to bilirubin levels were not pre-
sented. 
 
D0005d – How does defibrotide prophylaxis affect  
the incidence of GVHD? 
All included prophylaxis studies evaluated the incidence of GVHD. Results 
of the RCT showed that patients who received defibrotide prophylaxis had a 
lower incidence and severity of acute GVHD by 30 days and 100 days than 
patients of the control group (in which patients received defibrotide for treat-
ment of VOD). Incidence of acute GVHD by day +30 was 34% in the defib-
rotide arm compared to 52% in the control arm (p=.0057). By day + 100, the 
incidence was 47% in the defibrotide group and 65% in the control group 
(p=.0046). The incidence of chronic GVHD did not differ between the groups 
by 180 days. Corticosteroids (prescribed predominantely for acute GVHD) 
were used in 37% of defibrotide group patients and in 48% of control group 
patients [15].  
Chalandon et al. reported an incidence of acute GVHD grade ≥II of 34% in 
the study group versus 38% in the control group (p=.58). All included pa-
tients received GVHD prophylaxis, most patients were treated with cyclo-
sporine A and short-course methotrexate with or without other agents [35]. 
Qureshi et al. reported the occurrence of GVHD in two patients of the de-
fibrotide group (no information was provided for the occurrence of GVHD 
in the control group) [34]. 
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Health-related quality of life 
D0012 – What is the effect of defibrotide on  
generic health-related quality of life? 
No evidence was found to answer this research question.  
 
D0013 – What is the effect of defibrotide on  
disease-specific quality of life? 
No evidence was found to answer this research question. 
 
no evidence for 
assessing quality of life 




Element ID Research question 
Importance 
2 = critical 
1 = important 
C0008a How safe is defibrotide for the prophylaxis of VOD in comparison to 
the comparators? 
2 
C0008b How safe is defibrotide for the treatment of VOD in comparison to 
the comparators? 
2 
C0002 Are the harms related to the dosage or frequency of applying 
defibrotide? 
2 
C0004 How does the frequency or severity of harms change over time or in 
different settings? 
1 
C0005 What are the susceptible patient groups that are more likely to be 
harmed through the use of the technology? 
1 
B0010 What kind of data/records and/or registry are needed to monitor the 
use of the technology and the comparator? 
1 
 
The following crucial outcomes were used as evidence to derive a  
recommendation for the prophylaxis and treatment with defibrotide: 
 Severe AEs 
 Treatment-related mortality. 
In order to assess the relative effectiveness of an intervention, balancing harms 
against benefits is crucial. Serious AEs and treatment-related mortality are 
of special importance and were thus considered as crucial for assessing the 
safety of defibrotide [39] . 
 
Sources 
The information for this chapter was retrieved by a systematic literature search 
in four databases: Medline via Ovid, Embase, The Cochrane Library and 
CRD (DARE, NHS-EED, HTA), and was complemented by a Scopus search.  
 
Analysis 
To evaluate the safety of defibrotide for the treatment and prevention of VOD, 
data from the included studies were extracted in Tables A1-1, A1-2 and A1-3. 
No further analysis was performed. Internal validity of the included studies 
was assessed in Tables A2-1, A2-2 and A2-3 according to the Risk of Bias tool 
from the Cochrane Collaboration [31] for randomised controlled trials and 
for non-randomised studies according to a checklist used by EUnetHTA. The 
strength of evidence of safety was assessed according to the GRADE meth-
odology [33]. 
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Synthesis 
The research questions were answered in plain text format, based on the re-





For assessing the safety of defibrotide for the prophylaxis and treatment of 
VOD, the same studies were included as for effectiveness (see Chapter 4.2). 
Study characteristics and results of included studies are displayed in Tables 
A1-1, A1-2 and A1-3. Of note, the numbers of AEs extracted from the RCT 
have been measured after defibrotide treatment was administered in both 
study arms to all patients who had developed VOD. 
 
Patient safety 
C0008a – How safe is defibrotide for the prophylaxis  
of VOD in comparison to the comparators? 
Only the RCT presented numbers on overall AEs which were observed in 
87% (treatment group) and 88% (control group) respectively [15]. 37% of pa-
tients in both groups experienced severe AEs (grade 3), whereas the two oth-
er studies did report that no grade 3 or 4 AEs occurred [34, 35]. However, 
treatment-related AEs of any grade which were reported only in the RCT oc-
curred in only 6% in the treatment group and 4% in the control group [15]. 
Severe treatment-related AEs (Grade 3) occurred in 2% of defibrotide arm 
patients and in 3% of control arm patients. However, these numbers have 
been measured after defibrotide treatment was administered in both study 
arms to all patients who had developed VOD. The most common drug-relat-
ed AEs were gastrointestinal haemorrhage and epistaxis in the defibrotide 
group and gastrointestinal haemorrhage and prolonged activated partial throm-
boplastin time in the control group.  
Data on treatment-related mortality was available for 460 patients overall 
[15, 35]. In one study [35], treatment-related mortality was 14% in the study 
group and 28% in the control group; in the RCT 1% died in the defibrotide 
group and 0% in the control group (measured after defibrotide was adminis-
tered in both study arms for the treatment of all patients who had developed 
VOD). 
 
C0008b – How safe is defibrotide for the treatment of VOD in 
comparison to the comparators? 
In one of the studies with a total of 151 patients, overall AEs were reported 
in 97% of patients [37]. In 89%, AEs were of grade 3–4 without a difference 
between the doses used (most common were renal failure, hypotension, hy-
poxia, and other pulmonary events), 17% of patients experienced grade 5 AEs. 
Treatment-related AEs were stated in only one publication and occurred in 
8% of patients overall, 7% in lower-dose arm and 10% in higher-dose arm 
[37]. Treatment-related AEs of grade 3–4 were reported in 3% of patients 
RCT:  
treatment-related AEs in 
6% (treatment group) 
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overall (3% in lower-dose arm and 4% in higher-dose arm). No treatment-re-
lated deaths were reported in the same publication. Treatment-related bleed-
ing of grade 3–4 was reported in 1% of all treated patients [37]. 
From the prospective case series of 88 patients with severe VOD, no exact 
safety data was reported [36]. At the time of defibrotide initiation, all patients 
were seriously ill; they were either thrombocytopenic, platelet-transfusion- 
or plasma product-dependent and/or uremic. The authors noted that “serious 
grade 3 or 4 AEs that occurred during treatment were those commonly ob-
served in such critically ill patients in the post-transplantation setting (e.g., 
bacteraemia, acute renal failure and pulmonary oedema) and were not at-
tributed to defibrotide by the treating physicians” [36]. 
 
C0002 – Are the harms related to the dosage or frequency  
of applying defibrotide? 
Based on the current evidence, no definite conclusions can be drawn concern-
ing any difference in harms in relation to the dosage. AEs were poorly de-
scribed in some studies; the number of patients treated was overall rather 
small and patients’ characteristics differed considerably to allow any differ-
entiation. However, in the study comparing defibrotide at 25 mg/kg/day to 
40 mg/kg/day, the occurrence of AEs did not differ significantly between the 
two groups, with the exception of hypoxia [37]. 
 
C0004 – How does the frequency or severity of harms change  
over time or in different settings? 
No evidence was found to answer this research question.  
 
C0005 – What are the susceptible patient groups that are  
more likely to be harmed through the use of the technology? 
Even though treatment-related AEs did not differ between adults and paedi-
atric patients, paediatric patients were more likely to experience bleeding, 
hypotension and expected AEs in the dose-finding study with 151 patients 
overall [37].  
 
C0007 – Are defibrotide and comparators associated  
with user-dependent harms? 
No unequivocal tool for the diagnosis of VOD exists. Depending on whether 
the Baltimore or the Seattle criteria are used, different sensitivities and spec-
ificities can be expected [23, 24]. Misdiagnoses will therefore result in either 
foregoing potentially effective therapies or in putting patients at risk of re-
ceiving unnecessary and potentially harmful therapies. However, no evidence 
was found to answer the questions of whether physician experience and/or 
the criteria applied have any influence on the harms of defibrotide.  
 
no exact safety  
data available from 
prospective case series 
harms in relation to 
dosage: no conclusions 
can be drawn 
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Investments and tools required 
B0010 – What kind of data/records and/or registry are needed to monitor 
the use of the technology and the comparator? 
VOD is a rare disease with only a small number of affected patients. Since 
market authorisation was granted under exceptional circumstances, RCTs 
are unlikely to be feasible. As stated in the European Assessment Report, the 
market authorisation holder was required to implement a patient registry pri-
or to launch in order to investigate long-term safety, health outcomes and 
patterns of utilisation. The EMA requires a multi-centre, multinational and 
prospective observational disease registry of patients diagnosed with severe 
hepatic VOD following HSCT and enrol patients treated with defibrotide, 





registry for severe 
hepatic VOD 
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6 Quality of evidence 
The strength of evidence was rated according to the GRADE (Grading of Rec-
ommendations Assessment, Development and Evaluation) scheme [33] for 
each endpoint individually. Each study was rated by two independent re-
searchers. In case of disagreement, a third researcher was involved to solve 
the difference. A more detailed list of criteria applied can be found in the re 
commendation of the GRADE Working Group [33]. The ranking according 
to the GRADE scheme for the research question can be found in Table 6-1 
and Table 6-2. 
GRADE uses four categories to rank the strength of evidence: 
 High = We are very confident that the true effect lies close to that of 
the estimate of the effect;  
 Moderate = We are moderately confident in the effect estimate: the 
true effect is likely to be close to the estimate of the effect, but there 
is a possibility that it is substantially different;  
 Low = Our confidence in the effect estimate is limited: the true effect 
may be substantially different from the estimate of the effect;  
 Very low = Evidence either is unavailable or does not permit a  
conclusion. 
 
Defibrotide for VOD prophylaxis 
Overall, the strength of evidence for the effectiveness and safety of defibrotide 
for the prophylaxis of VOD was very low to moderate.  
 
Defibrotide for VOD treatment 
Overall, the strength of evidence for the effectiveness and safety of defibrotide 
for the treatment of VOD is very low. 
 
 
quality of evidence  
was rated according  
to GRADE 
quality of evidence for 
defibrotide prophylaxis 
was very low to 
moderate 
the strength of evidence 
for the effectiveness of 
defibrotide treatment 


































Table 6-1: Evidence profile: efficacy and safety of defibrotide for the prophylaxis of VOD 
No of studies/ 






Overall mortality at 100 days, % (I vs. C) 
1/356 RCT 10 vs. 10 
p=.9 
No serious limitations Only one study Major uncertainty (-2)1, 2 None  Low 
2/207 Historic controls 0–8 vs. 4–19 
p=.07 
Serious limitations (-1)3 No important inconsistency4 Direct None Very low 
Disease-specific mortality, % (I vs. C) 
1/356 RCT 2 vs. 6 
p=.1 
No serious limitations Only one study Major uncertainty (-2)1, 2 None  Low 
1/104 Historic control 0 vs. 6 Serious limitations (-1)3 Only one study Direct None Very low 
Incidence of VOD, % (I vs. C) 
1/356 RCT 12 vs. 20 
Risk difference:  
-7.7; z-test p=.048 
No serious limitations Only one study Direct Imprecise results (-1)5 Moderate 
2/207 Historic controls 0–4 vs. 7–19 
p=.001 
Serious limitations (-1)3 No important inconsistency4 Direct None Very low 
Safety 
Averse events grade 3–4, % (I vs. C) 
1/356 RCT 37 vs. 37 No serious limitations Only one study Major uncertainty (-2)1, 2 None  Low 
1/103 Historic control 0  Serious limitations (-1)3 Only one study Direct None Very low 
Treatment-related mortality, % (I vs. C) 
1/356 RCT 1 vs. 0 No serious limitations Only one study Major uncertainty (-2)1, 2 None  Low 
1/104 Historic control 14 vs. 28 
p=.075 
Serious limitations (-1)3 Only one study Direct None Very low 
I= intervention; C= control; RCT= randomised controlled trial; P = p -value 
 
1 = Patients in both groups (I 13% vs. C 20%) received therapeutic defibrotide once VOD occurred; AEs were reported for defibrotide after it was received following diagnosis of VOD. 
2 = Concomitant UDCA was administered in both groups. 
3 =Historic controls, unclear follow-up, unclear concomitant therapies, missing data on baseline characteristics or differences at baseline  
4 = Differences can be explained by different comparators used and by different patient characteristics  
















Table 6-2: Evidence profile: efficacy and safety of defibrotide for the treatment of VOD 
No of studies/ 
patients Study design 
Estimate  






Overall mortality at 100 days, %  
2/239 RCT1,  
prospective case series 
58–65 Serious limitations (-1)2, 3 No important 
inconsistency 
Indirect None  Very low 
Disease-specific mortality, % 
1/151 RCT1 28–29 Serious limitations (-1)2, 3, 4 Only one study Indirect None Very low 
Resolution of VOD, % 
2/239 RCT1,  
prospective case series 
36–46 Serious limitations (-1)2, 3, 4 No important 
inconsistency 
Indirect None  Very low 
Safety 
Averse events grade 3–4, %  
1/151 RCT1 89 Serious limitations (-1)2, 3, 4 Only one study Indirect None  Very low 
Treatment-related mortality, %  
1/151 RCT1 0 Serious limitations (-1)2, 3, 4 Only one study Indirect None Very low 
I= intervention; C= control; RCT= randomised controlled trial 
 
1 = Even though this study is a RCT, it was designed as dose-finding study; therefore, the comparator included is not relevant for the study question. The study is therefore treated as single-arm study. 
2 = Unclear whether patients were enrolled consecutively. 
3 = Lack of (a relevant) comparator does not allow conclusions to be drawn on the effectiveness of the intervention in comparison to other treatment options. 
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7 Discussion 
Defibrotide for the prophylaxis of VOD 
VOD is a serious and life-threatening disease, but no standard therapy is 
available for the prophylaxis of VOD. Even though UDCA and low-dose hep-
arin are used in clinical practice, they are not approved. Moreover, defibrotide 
has not been licensed for this indication, because the manufacturer withdrew 
the application for the prophylaxis of VOD. However, even though usage of 
defibrotide in this setting is off-label, the European School of Haematology 
and European Group for Blood and Marrow Transplantation handbook, as 
well and the British Committee for Standards in Haematology and the Brit-
ish Society for Blood and Marrow Transplantation, both recommend defib-
rotide for the prophylaxis of VOD for children (1A = strong recommendation 
with high quality of evidence) and for adults (2B = weak recommendation 
based on moderate quality of evidence) [8, 40]. 
Several risk factors for the development of VOD have been identified, amongst 
them age, type of conditioning regimen and previous liver disease. General-
ly, patients scheduled for HSCT should be assessed for risk factors for VOD. 
For patients at risk, reduced intensity conditioning regimens or treatment 
with treosulfan instead of busulfan could reduce the risk of VOD foremost in 
paediatric patients [8].  
The only RCT found for the prophylaxis of VOD was conducted in children 
<18 years with at least one risk factor for VOD. With 12% in the interven-
tion group and 20% in the control group, the incidence of VOD was closely 
reaching statistical significance [15]. Concerning mortality outcomes, no dif-
ference was found between defibrotide and no prophylaxis. However, these 
outcomes may have been biased due to the administration of therapeutic de-
fibrotide to patients in both groups once they had developed VOD. Addition-
ally, one-third of patients in each group received concomitant UDCA.  
Two further and historical controlled trials were identified as supportive ev-
idence [34, 35]. VOD incidence was reduced in one of these trials which had 
also included adults [35], whereas the other did not find a statistically signif-
icant difference [34]. Overall mortality at 100 days did not show an advantage 
for defibrotide prophylaxis in these studies and disease-related mortality was 
0% in the intervention group in comparison to 6% in the control group in 
one study. However, study limitations are attributable to unclear follow-up, 
unclear concomitant therapies and missing data on baseline characteristics or 
differences at baseline. Furthermore, in two studies the low number of pa-
tients and the matching of intervention group patients with historical con-
trols impact on the confidence in these results.  
In terms of safety, two studies [34, 35] did not provide exact data on the oc-
currence of overall AEs. Results from the RCT [15] showed that 87–88% of 
patients included in the RCT had AEs, 37% had severe AEs and treatment-
related AEs were reported from 4–6% of patients. Severe treatment-related 
AEs (Grade 3) occurred in 2% of defibrotide arm patients and in 3% of con-
trol arm patients; the low incidences of treatment-related AEs indicate that 
defibrotide is well-tolerated. However, these numbers have been measured af-
ter defibrotide treatment was administered in both study arms to all patients 
who had developed VOD. Statistical significance was calculated for the inci-
dence of haemorrhage (the most common AE, regarded by the investigator as 
no standard therapy  




and treosulfan treatment 
could reduce risk of 
VOD 
different results for 
overall mortality among 
included studies 
RCT:  
4–6% of patients had 
treatment-related AEs 
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possibly, likely or certainly related to defibrotide) and for the incidence of 
transplant-associated microangiopathy; both p-values were not statistically 
significant. 
 
Defibrotide for the treatment of VOD 
For the treatment of hepatic VOD, a disease with high mortality rates, sup-
portive care is the mainstay of therapy. Defibrotide is currently the only ap-
proved drug for the treatment of severe VOD and it is also recommended by 
different European Societies [8, 40]. The British Committee for Standards in 
Haematology and the British Society for Blood and Marrow Transplantation 
recommend defibrotide for the treatment of VOD in adults and children (level 
of recommendation is 1B = strong recommendation with moderate quality of 
evidence) [8]. 
EMAs licensing decision was based on a phase 3 historical-controlled study 
including 44 children and 58 adult patients with severe VOD post-HSCT, 
compared to 32 historical control patients. This study was only published as 
an abstract and therefore not included in this assessment [1]. Complete re-
sponses (i.e., total bilirubin <2 mg/dL and the resolution of MOF) were ob-
served in 24% (24/102) of the patients treated with defibrotide in comparison 
to 9% (3/32) in the historical control (p=0.013). Day+100 survival rate was 
38% (39/102) versus 25.0% (8/32) (p=0.034) [2]. 
Only two studies were included in this assessment [36, 37]. In both, the de-
fibrotide treatment of VOD showed similar rates for overall mortality on day 
+100 (58–65%). For disease-specific mortality + 100 days, results were only 
available from the dose-finding RCT (28–29%) [37]. VOD resolution was re-
ported in 36–46% of patients. 
AEs were described in one of the studies, the dose-finding trial [37]. Overall, 
97% experienced AEs and 89% were of grade 3 or 4. Although 8% of patients 
were considered as having treatment-related AEs, no treatment-related deaths 
were observed. Treatment-related AEs of grade 3–4 occurred in 3% of all pa-
tients. Considering the low incidences of treatment-related AEs, defibrotide 
has a favourable safety profile. 
Both of the included studies were not appropriate for evaluating the effec-
tiveness of defibrotide treatment due to the lack of a comparator. The RCT 
[37] was designed as a dose-finding study and, therefore, the included com-
parator is not relevant for the study question. Furthermore, the outcome as-
sessors were not blinded. In the prospective case series [36], it is unclear 
whether patients were enrolled consecutively.  
 
  
defibrotide approved  
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2 included studies: 
similar rates for overall 
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General discussion  
Currently, the evidence for both possible indications of defibrotide is scarce. 
However, defibrotide received orphan drug status for both indications and the 
EMA has granted marketing authorisation “under exceptional circumstanc-
es”. This market authorisation applies to “products for which the applicant 
can demonstrate in this application that he is unable to provide comprehen-
sive data on the efficacy and safety under normal conditions of use, because: 
 the indications for which the product in question is intended are en-
countered so rarely that the applicant cannot reasonably be expected 
to provide comprehensive evidence, or 
 in the present state of scientific knowledge, comprehensive  
information cannot be provided, or 
 it would be contrary to generally accepted principles of medical  
ethics to collect such information” [41]. 
Due to the rarity of disease, RCTs, foremost for the therapy with defibrotide, 
are difficult to conduct. Currently, two defibrotide treatment studies (both 
single-arm), and one study, evaluating the efficacy and safety of defibrotide 
for the prophylaxis of VOD (parallel, randomised) are ongoing (see Appen-
dix Section “Ongoing research”). 
The paucity of evidence also leaves several questions unanswered.  
 Drug administration: Different dosages were used for prophylaxis as 
well as for the treatment of VOD, ranging from 10 mg/kg/day – over 25 
to 60 mg/kg/day. According to the British Committee for Standards 
in Haematology and the British Society for Blood and Marrow Trans-
plantation, defibrotide is recommended at a dose of 6.25 mg/kg four 
times daily for the prevention and treatment of VOD in children and 
adults. However, the guidelines mention that further work is required 
to investigate the optimal dose of defibrotide [8]. Furthermore, the du-
ration of administration differed. Thus, the optimal duration and the 
optimal dosage remain unknown, even though there are some indica-
tions that lower doses are associated with fewer adverse events [3]. In 
addition, defibrotide is also available as oral therapy, even though this 
route of administration was not used in any of the studies [8]. How 
these different applications affect outcomes has not been assessed.  
 Diagnosis: Different criteria exist for diagnosing VOD. Depending on 
the criteria used, a different set of patients will be identified. The Bal-
timore criteria identify more advanced cases of hepatic VOD than the 
modified Seattle criteria. Since clinical criteria may only become ap-
parent with a delay, the effectiveness of defibrotide may also differ de-
pending on the severity of disease at diagnosis and thus on the initia-
tion of therapy.  
 Prophylaxis versus treatment: A further question concerns whether de-
fibrotide therapy should be preferred over prophylaxis of VOD [26]. 
Since younger age has been identified as a risk factor for VOD, pro-
phylaxis in this age cohort may yield better outcomes than therapy [3]. 
Also, a more preferable safety profile can be expected for patients re-
ceiving prophylactic therapy than for those with established severe 
VOD. In addition, it remains unclear how patients previously treated 
with defibrotide prophylaxis will respond to defibrotide therapy. In 
any case, risk stratification and, consequently, the reduction of risk-
factors for VOD are keys to minimise the occurrence of VOD [25].  
Defibrotide for the treatment and prophylaxis of hepatic veno-occlusive disease 
52 LBI-HTA | 2015 
 Long-term safety: No long-term safety data are currently available for 
defibrotide. Especially for young patients and in the light of missing 
data on the optimal duration of prophylactic therapy with defibrotide, 
the question concerning long-term safety outcomes is of utmost rele-
vance. 
 Population: Even though there is no plausible rationale why defibro-
tide should act differently in an adult and a paediatric population, the 
RCT on defibrotide prophylaxis has assessed this prophylactic regi-
men only in children at high risk for VOD. Since age has been identi-
fied as a risk factor for the development of VOD and data on side ef-
fects for different age groups are scarce, the effectiveness of defibro-
tide remains unknown in children at low risk and in an adult popula-
tion [3]. Concerning prophylaxis, guidelines recommend defibrotide 
for high-risk patients only.  
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8 Recommendation 
In Table 8-1 and Table 8-2 the schemes for recommendations are displayed 
and the according choices are highlighted. 
 
Defibrotide for VOD prophylaxis 
Table 8-1: Evidence-based recommendations 
  The inclusion in the catalogue of benefits is recommended.  
 
The inclusion in the catalogue of benefits is recommended with 
restrictions. 
X The inclusion in the catalogue of benefits is currently not recommended. 
 The inclusion in the catalogue of benefits is not recommended. 
 
Reasoning: 
Even though there are indications that the prophylaxis of VOD with defib-
rotide reduces the incidence of VOD, a life-threatening disease, at least in 
children at high risk and few AEs are associated with this therapy, an inclu-
sion in the catalogue of benefits for an off-label indication cannot be recom-
mended.  
A re-evaluation is recommended when the licensing status of the drug changes.  
 
Defibrotide for VOD treatment 
Table 8-2: Evidence-based recommendations  
  The inclusion in the catalogue of benefits is recommended.  
X The inclusion in the catalogue of benefits is recommended with restrictions. 
 The inclusion in the catalogue of benefits is currently not recommended. 
 The inclusion in the catalogue of benefits is not recommended. 
 
Reasoning: 
The current evidence is not sufficient to evaluate the effectiveness and safety 
of defibrotide for the treatment of VOD. However, since VOD is a rare and 
life-threatening disease with no other therapeutic options available, defib-
rotide offers a new therapeutic approach for patients with severe VOD and 
targets an area of high unmet clinical need.  
The proper assessment of risk factors and, whenever possible, the avoidance 
of risk factors have to be ensured in all patients scheduled for HSCT or at 
risk for developing VOD. Data on outcomes, foremost on long-term safety, 
should be collected in a prospective patient registry. Re-evaluation is recom-
mended once these data become available. Thus, EMA website surveillance is 
also recommended to identify any change in the licensing status. Risk-sharing 
agreements are also indicated.  
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Evidence tables of individual studies included for clinical effectiveness and safety 
Table A1-1: VOD prophylaxis – results from RCTs 
Author, year, reference number Corbacioglu et al. [15] (2012) 
Country 28 centres in Europe (Austria, France, Germany, Ireland, Israel, Italy, Netherlands, Sweden, Switzerland, United Kingdom) 
Sponsor Gentium SpA, European Group for Blood and Marrow Transplantation 
Study design Multi-centre, phase III, open-label RCT, stratification according to centre and diagnosis of osteopetrosis 
Intervention (I) Defibrotide 25 mg/kg/day, in four divided i.v. infusions of 6.25 mg/kg over two hours 
Starting with the conditioning treatment and continued for 30 days after transplantation or at least for 14 days if discharged earlier 
Comparator (C) No prophylaxis 
Concomitant therapies UDCA was allowed 
when patients developed VOD; treatment with defibrotide at 25mg/kg was administered until complete recovery or death in both groups. 
Number of pts (I vs. C) 356 (180 vs. 176) 
Inclusion criteria Patients <18 years who had undergone myeloablative conditioning before allogeneic or autologous HSCT and had one or more risk 
factors for VOD 
Exclusion criteria NA 
Patient characteristics (I vs. C)  
Age of patients (median, yrs)  5.1 vs. 4.6 
Sex (female), % 39 vs. 43 
VOD high-risk criteria, % 
familial macrophage 
activity/osteopetrosis/adrenoleukodystrophy 
Second myeloablative transplantation 
Allogeneic HSCT for leukaemia >2nd relapse 
Pre-existing liver disease 
Previous abdominal irradiation 
Previous gemtuzumab treatment 
Conditioning with busulfan and 
melphalan/cyclophosphamide  
 
6/4/1 vs. 9/3/1 
 
14 vs. 13 
9 vs. 6 
23 vs. 31 
5 vs. 5 
6 vs. 3 
59 vs. 56 




68 vs. 67 
29 vs. 31 
                                                             


































Author, year, reference number Corbacioglu et al. [15] (2012) 
Additional medication, % concomitant UDCA: 31 vs. 32 
treatment with defibrotide: 13 vs. 20 
Evaluation of VOD Modified Seattle criteria + US + independent review committee to confirm diagnosis 
Follow-up after transplantation, days (median) 180 (range 28–1108, IQR 179–185) 
Loss to follow-up, n 4 vs. 0 
Outcomes (I vs. C) 
Efficacy 
Overall mortality at 100 days, n (%) 18 (10) vs. 17 (10), log-rank test p=0.9 
Disease-related mortality at 100 days, n (%)  4 (2) vs. 10 (6) p =0.1 
Incidence of VOD by 30 days after HSCT,  
n (%) 
VOD in patients with osteopetrosis, n (%) 
VOD by type of donor, n (%) 
Allogeneic HSCT 
Autologous HSCT 




22 (12) vs. 35 (20) 
(risk difference -7.7, 95% CI -15.3 to -0.1; log-rank test p=0.0507, Z test for competing risk analysis, p=0.0488 
1/7 (14) vs. 4/6 (67) 
 
15/180 (8) vs. 25/176 (14) 
7/180 (4) vs. 10/176 (6) 
 
9/46 (20) vs. 11/41 (27) 
10/91 (11) vs. 16/95 (17) 
3/43 (7) vs. 8/40 (20) 
Severity of VOD up to 100 days post HSCT p=0.034 
Incidence of acute GVHD by day +30, n (%) 
Incidence of acute GVHD by day +100, n (%) 
42 (34) vs. 61 (52) , p=0.0057 
57 (47) vs. 76 (65), p=0.0046 
Health-related quality of life - 
Safety 
All AEs, n (%) 154 (87) vs. 155 (88) 
AEs (grade 3), n (%) 66 (37) vs. 65 (37) 
Treatment-related mortality, n (%) 1 (1) vs. 0 (0) 
Treatment-related AEs, n (%) 10 (6) vs. 7 (4) 
Treatment-related AEs (grade 3), n (%) 4 (2) vs. 6 (3) 
AE= adverse event; CI= confidence interval; GVHD= graft-versus-host disease; HSCT= hematopoietic stem cell transplantation; IQR= interquartile range; i.v. = intravenous;  

















Table A1-2: VOD prophylaxis – results from non-randomised clinical trials 
Author, year, reference number Qureshi 2008 [34] Chalandon 2004 [35] 
Country United Kingdom Switzerland 
Sponsor NA NA 
Study design Prospective, historically-controlled 
(consecutive inclusion of intervention group April 2004–
December 2005; control group from November 2001–April 2004) 
Prospective, historically-controlled 
(consecutive inclusion of intervention group October 1999–June 2002; 
controls group from February 1997–September 1999) 
Intervention Defibrotide 20 mg/kg/day from start of condition treatment 
until day 28 post-stem cell infusion 
Defibrotide 200–400 mg (10–25 mg/kg/d in children weighing 30 kg), 
i.v. over 2 hours 4 times daily starting one day before conditioning 
treatment to day +20 after transplantation 
+ 
Low-dose heparin (5000 IU i.v. continuously for 24 hours if weight 
<70kg or 10000 IU if weight >70 kg) 
Comparator High-risk patients (busulfan conditioning; deranged baseline 
transaminase levels) received UDCA (15 mg/kg/once daily) and 
tinziparin (50μ /kg/once daily) 
Low-dose heparin (5000 IU i.v. continuously for 24 hours if weight 
<70kg or 10000 IU if weight >70 kg) 
Dose modification In 4 of 47 patients who developed clinical VOD, defibrotide 
dose was increased to treatment dose of 40–60 mg/kg/day 
Higher risk patient received higher dose (400 mg 4 times daily), 
standard risk patients received standard doses (200 mg 4 times daily) 
Concomitant therapies NA antibiotics, liposomal amphotericin B, acyclovir, cytomegalovirus-
negative blood products, parenteral nutrition, fungal prophylaxis, 
foscarnet if required, growth factors 
Number of pts (I vs. C) 103 (47 vs. 56) 104 (52 vs. 52) 
Inclusion criteria Children undergoing HSCT from April 2004–December 2005 Patients with hematologic malignancies who underwent allogeneic 
peripheral blood stem cell or bone marrow transplantation from 
October 1999–June 2002 
Exclusion criteria NA NA 
Patient characteristics (I vs. C) Age, % Median age, years 
 1–6 y: 47 vs. 34 
7–12 y: 30 vs. 43 
13–18 y: 23 vs. 23 
 
36.5 (range 5–60) vs. 37 (range 4–60) 
Sex (female), % 30 vs. 43 46 vs. 27 
Risk factors, % 
Treatment with busulfan/ 
cyclophosphamide  
Total body irradiation 





30 vs. 34 
 
15 vs. 21/81 vs. 73 
 
100 vs. 100 
13 vs. 12 




53 vs. 48 
47 vs. 52 
 


































Author, year, reference number Qureshi 2008 [34] Chalandon 2004 [35] 
VOD risk status, % Low risk: 30 vs. 36 
Intermediate risk: 51 vs. 46 
High risk: 19 vs. 182 
Standard risk: 42 vs. 54 
High risk: 58 vs. 463 
Evaluation of VOD Modified Seattle criteria + US to confirm diagnosis Baltimore criteria + US to confirm diagnosis 
Follow-up, months NA Median: 21 (range 9–41) vs. 57 (range 43–70) 
Loss to follow-up, n NA NA 
Outcomes (I vs. C) 
Effectiveness 
Overall mortality at 100 days, n (%) 0 (0) vs. 2 (4) NA (8) vs. NA (19); p=0.07 
Disease-related mortality, n (%) NA 0 vs. 3 (6) 
Incidence of VOD, n (%) 2 (4) vs. 4 (7) 0 (0) vs. 10 (19) 
p=0.001 
Severity of VOD, n (%) NA NA 
Incidence of GVHD, n (%) 2 (4) vs. NA Acute GVHD grade ≥ II: 
NA (34) vs. NA (38), p=0.58 
Health-related quality of life  NA NA 
Safety 
Overall AEs, n (%) NA NA 
AEs (grade 3–4), n (%) NA NA 
Treatment-related mortality, n (%)  NA NA (14) vs. NA (28), p=0.075 
Treatment-related AEs, n (%) NA NA 
Treatment-related AEs grade 3 or 4, n (%) NA 0 
AE= adverse event; GVHD= graft-versus-host disease; IU= international unit; i.v. = intravenous; NA= data not available; p= p value; UDCA= ursodeoxycholic acid;  
VOD= veno-occlusive disease 
 
 
                                                             
2 Intermediate risk: allogeneic transplant; high risk: abnormal transaminase levels at baseline 
















Table A1-3: Defibrotide for the treatment of VOD – results from uncontrolled trials 
Author, year, reference number Richardson 2010 [37] Richardson 2002 [36] 
Country USA USA 
Sponsor Gentium SpA, Orphan Drug Product Grant,  
Richard Corman Multiple Myeloma Research Fund 
Gentium SpA provided defibrotide 
Study design Multi-centre, randomised, dose-finding, open-label phase II Prospective, case series 
Intervention Defibrotide 25 mg/kg/day and 40 mg/kg/day 
Starting dose was 2.5 mg/kg every 6 hours for 4 doses 
(total dose, 10 mg/kg), increased to 6.25 mg/kg every 6 
hours (total dose, 25 mg/kg/day) in arm A and to 10 mg/kg 
every 6 hours (total dose 40 mg/kg/day) in arm B for a 
minimum of 14 days or until achievement of CR, or until 
progression of VOD, unacceptable toxicity (recurrent 
grade 3/4 AEs considered likely or definitely related to 
defibrotide), or comorbidities precluded further treatment 
Defibrotide 10 mg/kg/day as 4 divided doses; dose was increased 
incrementally to a max. potential total daily dose of 60 mg/kg for a 
minimum of 14 days. 
Comparator None None 
Additional medication transfusions transfusions 
Dose modification NA Dose was increased incrementally to a maximum potential daily dose of 
60 mg/kg 
Number of pts 151 
(75 25 mg/kg defibrotide vs. 74 40 mg/kg defibrotide) 
88 
Inclusion criteria Adult or paediatric patients after HSCT with a clinical 
diagnosis of hepatic VOD (according to clinical criteria for 
evaluation of VOD or jaundice + US +1 further diagnostic 
criterion or biopsy confirmed VOD), with a predicted risk 
≥30% according to the Bearman model or if they had MOF 
Adult patients and children after HSCT with a clinical diagnosis of VOD4 
treated from March 1995–May 2001 on an emergency use basis 
Exclusion criteria Uncontrolled bleeding, hemodynamic instability, grade  
B–D GVHD, intubation for documented intrinsic lung 
disease, grade 4 neurotoxicity, previous or concomitant 
systemic t-PA therapy, concomitant use of heparin or 
other anticoagulants 
Uncontrolled bleeding, hemodynamic instability 
Patient characteristics    
Age median, yrs (range) 34 (0–63) 35 (8 months to 62 years) 
Sex, female, % 43 47 
                                                             
4 Based on jaundice (bilirubin ≥34.2 μM), hepatomegaly and/or right upper quadrant pain, and ≥5% weight gain from admission, with or without ascites. Patients who met at least 
two criteria and had a liver biopsy were also eligible. Patients not addressed by the Bearman model were eligible if VOD was considered their major clinical problem and organ 
failure was present in at least one other organ system. Patients with a concurrent, potential confounding cause of liver dysfunction such as GVHD or inconsistent findings evident 


































Author, year, reference number Richardson 2010 [37] Richardson 2002 [36] 
Risk factors, % 
Treatment with busulfan/ 
cyclophosphamide  
TBI 




















Duration of treatment, median, days Arm A: 19 (range 2–82) 
Arm B: 20 (2–65) 
15 (range 1–139) 
VOD risk status, n NA High-risk population 
Evaluation of VOD Jaundice (total serum bilirubin ≥2 mg/dL) and at least two 
associated signs (ascites, weight gain >5 % from baseline, 
hepatomegaly or right upper quadrant pain, by day + 35 
post HSCT + US to confirm diagnosis 
Jaundice (bilirubin ≥34.2 μM), hepatomegaly and/or right upper quadrant 
pain, and ≥5% weight gain from admission, with or without ascites. Patients 
who met at least two criteria and had a liver biopsy, patients not addressed 
by the Bearman model were eligible if VOD was considered their major 
clinical problem and organ failure was present in at least one other organ 
system. Patients with a concurrent, potential confounding cause of liver 
dysfunction such as GVHD or inconsistent findings evident on ultrasound 
imaging were required to have biopsy-proven VOD to be considered eligible. 
Follow-up, months NA NA 
Loss to follow-up, n 4 vs.6 NA 
Outcomes (I vs. C) 
Efficacy 
Overall mortality on day +100, n (%)  87 (58) 57 (65) 
Disease-related mortality + 100 days, n (%) NA (28–29) NA 
Resolution of VOD, n (%) 65 (46)5 32 (36), 95% CI: 26%, 47%6 
Health-related quality of life, n (%) NA NA 
Safety 
Overall AEs, n (%) 144 (97) NA 
AEs (grade 3–4), % 132 (89) NA 
Treatment-related mortality, %  0 NA 
Treatment-related AEs, % 12 (8) NA 
Treatment-related AEs grade 3 or 4, n (%) 5 (3) 0 
AE= adverse event; CI= confidence interval; CR= complete response; GVHD= graft-versus-host-disease; MOF= multi-organ failure; NA= data not available;  
t-PA= tissue-plasminogen activator; TBI=total body irradiation; VOD= veno-occlusive disease 
                                                             
5 Defined as total serum bilirubin <2 mg/dL after initiation of defibrotide with resolution of VOD-related MOF 
















Risk of bias tables 
The internal validity of the included studies was judged by two independent researchers. In case of disagreement, a third researcher was involved to solve the dif-
ferences. A more detailed description of the criteria used to assess the internal validity of the individual study designs can be found in the Internal Manual of the 
LBI-HTA [30] and in the Guidelines of EUnetHTA [32].  











No other aspects 
which increase the 
risk of bias 
Risk of bias –  





Corbacioglu 2012 [15] Yes Yes No No Yes Yes No1 Low 
1 = Patients of both groups were treated with defibrotide when they developed VOD; thus for all outcomes besides the primary outcome, no formal conclusions on the effect can be drawn. 
Table A2-2: Risk of bias – study level (non-randomised studies) 
Study reference/ID 
How was the treatment 
group determined for 
each patient? 
Were treatment 
groups comparable  
at baseline? 
What steps were taken 
to minimise bias? 
Were all relevant 
outcomes reported? 
Whether intention-to-
treat was appropriately 
implemented? 
Any other problems 
that could put the study 
at a high risk of bias 
Prophylaxis of VOD 
Qureshi 2008 [34] Allocation determined 
according to date of 
treatment with 
consecutive inclusion for 
intervention group 
Unclear1 None Unclear2 Not applicable Low number of 
patients, intervention 
group patients matched 
with historical controls 
Chalandon 2004 [35] Allocation determined 
according to date of 
treatment with 
consecutive inclusion 
No None Unclear Not applicable Intervention group 
patients matched with 
historical controls 
Treatment of VOD 
Richardson 2010 [37] Unclear4 Not applicable Unclear5 Yes Not applicable - 
Richardson 2002 [36] Unclear6 Not applicable No Unclear Not applicable - 
1 = Only few baseline variables are listed and several risk factors for developing VOD are therefore not described. 
2 = Methods, outcomes, planned statistical analyses were not described. 
3 = Reported outcomes especially for adverse events are scarce. 
4 = In this dose-finding trial, no details are provided on how the allocation sequence was generated and how the patients were allocated. 
5 = Patients were stratified according to age and conditioning treatment, but the trial was open-label. 


































Table A2-3: Risk of bias – outcome level  
Outcome 
Trial 
Risk of bias –  
study level 






Other aspects  
according to risk of bias 
Risk of bias –  
outcome level 
Prophylaxis of VOD 
Incidence of VOD 
Corbacioglu 2012 [15] Low Low Low Low Low Low 
Qureshi 2008 [34] High High NA High High2 High 
Chalandon 2004 [35] High High NA Low Low High 
Overall mortality 
Corbacioglu 2012 [15] Low Low Low Low High1 High 
Qureshi 2008 [34] High Low NA High High2 High 
Chalandon [35] High Low NA Low Low High 
Disease-specific mortality 
Corbacioglu 2012 [15] Low Low Low Low High1 High 
Chalandon [35] High High NA Low Low High 
Grade 3–4 adverse events 
Corbacioglu 2012 [15] Low Low Low Low High1 High 
Qureshi 2008 [34] High High NA High High2 High 
Chalandon [35] High High NA Low Low High 
Treatment-related mortality  
Corbacioglu [15] Low Low Low Low High1 High 


















Risk of bias –  
study level 






Other aspects  
according to risk of bias 
Risk of bias –  
outcome level 
Treatment of VOD 
Overall mortality 
Richardson 2010 [37]3 High Low NA Low Low High 
Richardson 2002 [36]4 High Low NA Unclear Low High 
Disease-specific mortality 
Richardson 2010 [37]3 High High NA Low Low High 
Resolution of VOD 
Richardson 2010 [37]3 High High NA Low Low High 
Richardson 2002 [36]4 High Unclear NA Unclear Low High 
Grade 3–4 adverse events  
Richardson 2010 [37]3 High High NA Low Low High 
Treatment-related mortality 
Richardson 2010 [37]3 High High NA Low Low High 
1 = Patients of both groups were treated with defibrotide when they developed VOD;  
thus for all outcomes besides the primary outcome, no formal conclusions on the effect can be drawn. 
2 = Unclear follow-up for both groups; unclear concomitant therapies; unclear distribution of risk factors for VOD between both groups 
3 = Even though this was a randomised controlled trial, the primary objective of this study was to determine the optimal dosages and not to compare the intervention with other 
treatment options. Thus this study was treated like an uncontrolled trial. 
4 = Uncontrolled study design 
Abbreviations: NA = not applicable 
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Applicability table 
Table A3-1: Summary table characterising the applicability of a body of studies 
Domain Description of applicability of evidence 
Population Prophylaxis of VOD 
The age of patients in the three included studies showed a wide range from <1 year to 60 
years, which is consistent with the target population. It is unresolved as to whether the results 
of the RCT (paediatric study patients only) are applicable to adults.  
Historic controls served as comparators in two studies. One control was enrolled from 1999–2002 
and the other control group from 2001–2004. Since then, a better characterisation of risk factors 
for the development of VOD may limit the applicability with reduction of allogeneic HSCT in 
patients at high risk and use of dose-reduced conditioning regimens. 
Treatment of VOD 
The age of patients of both studies varied widely between eight months and 63 years, which is 
consistent to the target population.  
Intervention Prophylaxis of VOD 
In the included studies, different dosages of defibrotide were administered, ranging from  
10–25 mg/kg/day. Patients of two studies received additional medication (concomitant UDCA, 
low-dose heparin), which might have influenced the results. 
Treatment of VOD 
Administered dosages were different in the two included studies (25–60 mg/kg/day).  
All patients additionally received transfusions. 
Comparators Prophylaxis of VOD 
In the RCT, patients who received defibrotide for the prophylaxis of VOD were compared to 
patients who received no prophylaxis. The other two studies compared the use of defibrotide 
to historical control group patients who did not receive defibrotide. Historical control groups 
often differ significantly concerning co-intervention and prognostic factors, therefore, 
comparability is limited [30]. 
Treatment of VOD 
In the dose-finding RCT, the comparator included was not relevant for the study question.  
No control group was implemented in the prospective case series. Therefore, both studies  
were not appropriate to evaluate the effectiveness of defibrotide treatment. 
Outcomes Prophylaxis of VOD 
Overall mortality, disease-related mortality and the incidence of VOD were the outcomes most 
frequently reported. In the RCT, patients in the control group were treated with defibrotide 
once VOD developed. Outcomes other than the primary (i.e. incidencve of VOD), may have 
been biased.  
Treatment of VOD 
Overall mortality on day + 100 and resolution of VOD were the most important outcomes 
reported from the two included studies, aiming to reflect the effectiveness of defibrotide for 
VOD treatment. 
Setting Included studies were conducted either in Europe or the United States.  
Clinical settings were not described in all of the studies, but it is likely that all patients 
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Search Strategies 
Medline Search Strategy 
Database: Ovid MEDLINE(R) <1946 to November Week 3 2014>, Ovid MEDLINE(R) In-Process & 
Other Non-Indexed Citations <December 29, 2014>, Ovid MEDLINE(R) Daily Update <November 19, 
2014>, Ovid OLDMEDLINE(R) <1946 to 1965> 
Search Strategy: 
1 exp Hepatic Veno-Occlusive Disease/ (1125) 
2 veno-occlusive disease*.mp. (2785) 
3 venoocclusive disease*.mp. (219) 
4 VOD.mp. (1663) 
5 venous occlusion*.mp. (3860) 
6 1 or 2 or 3 or 4 or 5 (7859) 
7 Defitelio*.mp. (1) 
8 Defibrotide*.mp. (390) 
9 Defibrinotide*.mp. (1) 
10 proc#clide*.mp. (3) 
11 7 or 8 or 9 or 10 (391) 
12 6 and 11 (102) 
13 exp Clinical Trial/ or double-blind method/ or (clinical trial* or randomized controlled trial or 
multicenter study).pt. or exp Clinical Trials as Topic/ or ((randomi?ed adj7 trial*) or (controlled 
adj3 trial*) or (clinical adj2 trial*) or ((single or doubl* or tripl* or treb*) and (blind* or 
mask*))).ti,ab. (1247414) 
14 ((systematic adj3 literature) or systematic review* or meta-analy* or metaanaly* or "research 
synthesis" or ((information or data) adj3 synthesis) or (data adj2 extract*)).ti,ab. or (cinahl or 
(cochrane adj3 trial*) or embase or medline or psyclit or (psycinfo not "psycinfo database") or 
pubmed or scopus or "sociological abstracts" or "web of science").ab. or "cochrane database of 
systematic reviews".jn. or ((review adj5 (rationale or evidence)).ti,ab. and review.pt.) or meta-
analysis as topic/ or Meta-Analysis.pt. or review.pt. (2095639) 
15 13 or 14 (3133683) 
16 12 and 15 (37) 
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Embase Search Strategy 
No. Query Results Results Date 
#1 'clinical article'/de OR 'clinical trial'/de OR 'clinical trial (topic)'/de OR 
'cohort analysis'/de OR 'control group'/de OR 'controlled clinical trial'/de 
OR 'controlled study'/de OR 'in vivo study'/de OR 'major clinical 
study'/de OR 'meta analysis'/de OR 'multicenter study'/de OR 'phase 2 
clinical trial'/de OR 'phase 3 clinical trial'/de OR 'practice guideline'/de 
OR 'prospective study'/de OR 'randomized controlled trial (topic)'/de 
AND ('liver vein obstruction'/exp OR 'hepatic veno-occlusive disease' 
OR 'hepatic veno-occlusive diseases' OR 'veno-occlusive disease' OR 
'veno-occlusive diseases' OR 'venoocclusive disease' OR 'venoocclusive 
diseases' OR 'vein occlusion'/mj OR 'venous occlusion' OR 'venous 
occlusions' OR vod) AND ('defibrotide'/exp OR defitelio* OR 
defibrinotide* OR prociclide* OR procyclide* OR dasovas OR noravid) 
AND 'human'/de OR ('liver vein obstruction'/exp OR 'hepatic veno-
occlusive disease' OR 'hepatic veno-occlusive diseases' OR 'veno-
occlusive disease' OR 'veno-occlusive diseases' OR 'venoocclusive 
disease' OR 'venoocclusive diseases' OR 'vein occlusion'/mj OR 'venous 
occlusion' OR 'venous occlusions' OR vod AND ('defibrotide'/exp OR 
defitelio* OR defibrinotide* OR prociclide* OR procyclide* OR dasovas 
OR noravid) AND ([cochrane review]/lim OR [systematic review]/lim 
OR [controlled clinical trial]/lim OR [randomized controlled trial]/lim 
OR [meta analysis]/lim)) 
125 30 Dec 2014 
 
 
CRD Search Strategy 
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Search Strategy for the Cochrane Library 
Search Name: Defibrotide (Defitelio) for VOD 
Last Saved: 30/12/2014 17:00:41.921 
ID Search 
#1 MeSH descriptor: [Hepatic Veno-Occlusive Disease] explode all trees 
#2 veno-occlusive disease* (Word variations have been searched) 
#3 venoocclusive disease* (Word variations have been searched) 
#4 VOD (Word variations have been searched) 
#5 "venous occlusion" (Word variations have been searched) 
#6 #1 or #2 or #3 or #4 or #5  
#7 Defitelio* (Word variations have been searched) 
#8 Defibrotide* (Word variations have been searched) 
#9 Defibrinotide* (Word variations have been searched) 
#10 prociclide* (Word variations have been searched) 
#11 procyclide* (Word variations have been searched) 
#12 dasovas (Word variations have been searched) 
#13 noravid (Word variations have been searched) 
#14 #7 or #8 or #11  






































On 16 February 2015 a search in databases www.clinicaltrials.gov, clinicaltrialsregister.eu and www.who.int/ictrp was conducted;  
the following ongoing trials were identified: 
Table A5–1: Ongoing research 
Study identifier 
Sponsor/ 
Collaboration Time Study type 
Number  
of patients Age group Intervention Comparator 
Medical 
condition Endpoints 




Phase III,  
single-arm,  
open-label 

















20 Not applicable Defibrotide 
(treatment) 
NA VOD Survival at day 
100 post SCT in 
patients with 














VOD Incidence of 
VOD until day 
30 post SCT 
NA= data not available; DVT= deep vein thrombosis; SCT= stem cell transplantation; VOD= veno-occlusive disease 
 
 
 
